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ABSTRACT 
 
Chemical communication mediates the vast majority of collective bacterial 
behaviors, orchestrating gene expression and community functions. A fundamental 
understanding of how pathogens are able to do this underlies the philosophy of natural 
product chemistry, providing insights into novel mechanisms for controlling 
pathogenic bacterial infections. To increase the effectiveness of antibiotics, alternative 
therapeutic approaches can be used that target bacterial phenotypes associated with 
infections, including swarming motility and quiescence. This dissertation explores 
molecules that interfere with such phenotypes in two different pathogens: 
uropathogenic Escherichia coli (UPEC) and Vibrio parahaemolyticus. Increased 
understanding of how bacterial behaviors can be modulated in pathogens may 
significantly improve our ability to tackle these diseases. 
The first study, which is reported in chapter two, describes the role of 
peptidoglycan, a ubiquitous bacterial cell wall component, in facilitating the reversal 
of quiescence in UPEC. This study uses an in vitro model of the quiescent state to test 
isolated peptidoglycan as a chemical signaling molecule that reverses dormancy. A 
single purified peptide was isolated from cultures of UPEC using bioassay-guided 
fractionation and enzyme treatment. The tetrapeptide, Ala-Glu-DAP-Ala was found to 
be a potent proliferant that reverses quiescence in UPEC. This is the first reported 
compound to possess this bioactivity. 
Chapter three describes an investigation to better understand chemically-mediated 
bacteria-bacteria interactions between the marine bacteria Bacillus pumilus YP001 and 
Vibrio parahaemolyticus PSU5429.  The investigational approach used a combination 
  
of experimental methods, emphasizing Matrix-Assisted Laser Desorption Ionization-
Time of Flight Imaging Mass Spectrometry (MALDI-TOF IMS), whole genome 
analysis, and chemical isolations. The main finding showed that multiple compounds 
produced by the B. pumilus may act in concert to effect a lethal outcome on V. 
parahaemolyticus cells. When B. pumilus was grown in close proximity to the V. 
parahaemolyticus on an agar surface, secreted secondary metabolites induced 
swarming motility in the vibrio, chemically attracting toward a lethal zone containing 
an antibiotic. 
Chapter four describes whole genome sequencing and bioinformatics based 
secondary metabolite profiling of genetically unique bacteria strains isolated from the 
American lobster Homarus americanus. This body of work implicates potentially 
important genetic pathways for both pathogenic and commensal bacteria. Furthermore, 
these studies exemplify the use of next generation sequencing and biosynthetic 
pathways tools to probe the potential for bacteria to produce unique natural products. 
 
 
 
 
 
 iv 
 
ACKNOWLEDGMENTS 
 
This dissertation could not have been completed without the help, support, and 
guidance of a community. I would like to take the time to acknowledge several of the 
people who have helped and supported me throughout this journey.  
Firstly, to Dr. David C. Rowley for always being an outstanding mentor and 
friend. You have taught me so much about how to be a good teacher and researcher. 
You’ve allowed me to pursue my passion for going to sea, I don’t know that many 
advisors would have allowed such freedoms as going to sea for ten weeks per year 
without so much as a raised eyebrow. I am extremely grateful for Dave’s mentoring, 
support and guidance throughout my time at URI. I have grown a lot as a scientist and 
chemist within his lab. 
My other committee members Dr. Marta Gomez-Chiarri and Dr. Navindra P. 
Seeram, who have both provided excellent guidance and support throughout my time 
at URI. Dr. Matthew Bertin for providing tips and insights into projects and always 
being on hand to troubleshoot machine failures. Dr. Al Bach and Kim Andrews for 
their time and patience in training me, their hallway conversations and their work in 
maintaining the INBRE Core facility. 
Much of this work could not have been completed without collaborations with Dr. 
Jodi Camburg and Dr. Paul Cohen who’s expertise was invaluable to the project. Eric 
DiBiasio work tirelessly to achieve our goals of publishing a high impact manuscript. 
A vast body of work was completed by Mary Leatham-Jensen, Jim Johnson and Dr. 
 v 
 
Robert Deering to make this project possible. Members of the Rowley lab both past 
and present, have provided counseling and expertise throughout my time here. Outside 
collaborators including Dr. Valentina Petukhova, Dr. Abigail Green Saxena and Dr. 
Laura Sanchez at the University of Illinois at Chicago. Who’s research techniques and 
knowledge aided this research.  
To my brother, who has painstakingly edited my writing, constantly attempted to 
integrate such words as unprecedented. Your charisma is something that I will always 
channel while presenting science. Liz and Richard, who raised me to be the person 
that I am today and have looked out for me always. You have never questioned my 
path in life, always trusting that I knew what I wanted. You have all been powerful 
role models. Dad, your quiet brilliance has been an unspoken constant in my life, you 
have such passion for what you do. Mum, your intuition and dogged determination are 
something that I carry with me always. 
To my friends, mentors and the community of Woods Hole, who welcomed me 
into their homes and provided me with unparalleled support. I am incredibly fortunate 
to walk through life knowing that you will always have my back. To Athena, Lucy, 
Kirsten, Kimmy, Shannon, and Emily you taught me to sail, to know when to quit and 
to know when all you need is to look at the ocean. Your love and support has driven so 
many decisions in my life, you are like a family to me. Countless other people who 
have helped me along this path, both professionally and personally. A special thanks 
goes to Barbara Jones and Dr. Matthew Slater who have been amazing mentors. The 
crew of C279 and S287, we have lived a lifetimes worth of experiences together. Your 
 vi 
 
passion for teaching, ability to hold a community together and skills as shipmates have 
taught me that you can always dig deeper.  
I am incredibly fortunate to have so many mentors in my life, I am constantly 
impressed by each and every one of you. I wouldn’t have made it this far without you 
all. 
 
 vii 
 
PREFACE 
This dissertation has been written in the manuscript format as directed by the 
guidelines set forth by the graduate school of the University of Rhode Island. 
 
 
 
 
 
 
 viii 
 
TABLE OF CONTENTS 
 
ABSTRACT…………………………………………………………………………...ii 
ACKNOWLEDGMENTS…………………………………………………………...iv 
PREFACE……………………………………………………………………………vii 
TABLE OF CONTENTS…………………………………………………………..viii 
LIST OF TABLES……………………………………………………………………x 
LIST OF FIGURES………………………………………………………………...xiii 
CHAPTER 1 ……………………………………………………………………….....1 
 INTRODUCTION…………………………………………………………......1  
CHAPTER 2 ………………………………………………………………………...24 
 MANUSCRIPT 1: Peptidoglycan sensing prevents quiescence and promotes 
quorum-dependent growth of uropathogenic Escherichia coli……………………….25 
CHAPTER 3 ………………………………………………………………………...79 
 MANUSCRIPT 2: Production of lipopeptides and antibiotics by a marine 
Bacillus pumilus creates a ‘catch and kill’ effect on a Vibrio parahaemolyticus…….80 
CHAPTER 4 ……………………………………………………………………….154 
 MANUSCRIPT 3: Draft genome sequence of the putative marine pathogen 
Aquimarina sp. I32.4 ………………………………………………………………..155 
 MANUSCRIPT 4: Draft genome sequence of the putative marine pathogen 
Thalassobius sp. I31.1 ………………………………………………………………162 
 ix 
 
 MANUSCRIPT 5: Draft genome sequence of Loktanella maritima YPC211, a 
commensal bacterium of the American lobster (Homarus americanus) …………...178 
CONCLUDING REMARKS ……………………………………………………..174 
APPENDICIES …………………………………………………………………….176 
 APPENDIX A ………………………………………………………………176 
 APPENDIX B ………………………………………………………………186 
 APPENDIX C ………………………………………………………………202 
 x 
 
LIST OF TABLES 
 
TABLE                 PAGE 
INTRODUCTION 
Table 1. Known chemical signaling functions of compounds from peptidoglycan
 ............................................................................................................................. 22 
MANUSCRIPT 1 
Table 1. Prevalence of quiescence among UPEC ST131 isolates ....................... 60 
Table S1. E. coli strains and plasmids used for genetic analysis and constructions 
in this study .......................................................................................................... 68 
MANUSCRIPT 2 
Table 1. Genes encoding the surfactin biosynthetic gene cluster in B. pumilus 
YP001, their proposed function and homology to the biosynthetic genes of B. 
amyloloquefaciens BGC0000443. Alignments carried out in NCBI-nBLAST  118 
Table 2. Genes encoding the amicoumacin biosynthetic gene cluster in B. pumilus 
YP001, their proposed function and homology to the biosynthetic genes of B. 
subtilis subsp. Inaquosoum KCTC 13429. Alignments carried out in NCBI-
nBLAST ............................................................................................................. 119 
Table S1. Amino acid alignments for amicoumacin production from B. pumilus 
YP001. ............................................................................................................... 128 
 xi 
 
TABLE                 PAGE 
Table S2. Amino acid alignments for surfactin production from B. pumilus YP001   
 ................................................................................................................................... 119 
Table S3. 1H and 13C NMR data (δ in ppm, J in Hz) for compound 1 in DMSO-d6. 
 ................................................................................................................................... 133 
Table S4. NMR Data for amicoumacin B (500 MHz) in DMSO-d6 .……………...152 
Table S5. NMR Data for AI-77-F (500 MHz) in DMSO-d6 .…………….………...153 
APPENDIX B 
Table 1. Zones of inhibition (mm) from screened lobster isolates (5 µL spot plates) 
against Aquimarina sp. strain I32.4, Thalassobius sp. I31.1 and Vibrio anguillarium 
NB10Sm.. .................................................................................................................. 193 
Table 2. Optimizing growth conditions for Aquimarina ‘homaria’. Symbols 
correspond with + (Low Clumps), ++ (Clumps), +++ (High Clumps) and + (Low 
Growth), ++ (Growth), +++ (High Growth)... .......................................................... 194 
Table 3. Data obtained from NCBI for all known Aquimarina genomes and analyzed 
using the antiSMASH cluster analysis database.* Aquimarina pacifica and 
Aquimarina agarilytica possess no know biosynthetic gene clusters (BGCs).. ....... 195 
Table 4. Data obtained from NCBI for all known Thalassobius sp. genomes and 
analyzed using the antiSMASH cluster analysis database. ....................................... 196 
TABLE                 PAGE 
 xii 
 
Table 5. Monoculture XAD16 extracts activity against V. anguillarum NB10Sm. . 198 
Table 6. Adult H. americanus trial carried out over 12 days. ................................... 200 
Table 7. Single strain testing of potential probiotics against PL lobsters assessing 
mortality over 3 days.. ............................................................................................... 201 
Table 8. Ability of probiotic treatment to protect PL lobsters from challenge with the 
putative pathogen Thalassobius I31.1 mortality.. ..................................................... 202 
APPENDIX C 
Table 1. Data obtained from NCBI for all known genomes of Loktanella and analyzed 
using the antiSMASH cluster analysis database.. ..................................................... 211
  
 
xiii
LIST OF FIGURES 
 
FIGURE                 PAGE 
INTRODUCTION 
Figure 1. Model of bacterial chemical communication. Chemical signals in the form of 
autoinducers and secondary metabolites that act as inter- and intra-species 
communications to facilitate phenotypic changes....................................................... 20 
Figure 2. The structure of peptidoglycan. A) A single muropeptide disaccharide 
pentapeptide. B) The structure of peptidoglycan within the cell wall, showing the 
dibasic amino acid cross-link between strands that forms the structure rigidity. ....... 21 
MANUSCRIPT 1 
Figure 1. The quorum-regulated quiescent state of E. coli CFT073 cells on glucose M9 
minimal agar is reversible ........................................................................................... 62 
Figure 2. Quiescent CFT073 cells are filamentous at 24 h ......................................... 63 
Figure 3. Quiescent CFT073 ∆lysP and ∆argP cells fail to proliferate with L-lysine 64 
Figure 4. ST131 strain JJ1886 displays quorum dependent growth ........................... 65 
Figure 5. Peptidoglycan fragments promote proliferation of quiescent JJ1886 cells . 66 
Figure S1. Quiescent CFT cells are filamentous at 48 h ............................................. 69 
Figure S2. UPEC strain growth in glucose M9 minimal media .................................. 71 
 
  
 
xiv
FIGURE                 PAGE 
Figure S3. D-lysine and diaminopimelic acid (DAP) fail to stimulate proliferation of 
CFT073 and JJ1886 cells on glucose M9 minimal agar ............................................. 72 
Figure S4. E. coli, B. subtilis and S. aureus peptidoglycan fragments stimulate 
proliferation of CFT073 and JJ1886 cells ................................................................... 73 
Figure S5. Peptidoglycan fragments, including S. aureus pentapeptide, stimulate 
proliferation of quiescent UPEC cells ......................................................................... 74 
Figure S6. Candidate proliferants tested for reversal of JJ1886 quiescence ............... 75 
Figure S7. E. coli peptidoglycan fragment analysis by tandem mass spectrometry ... 76 
Figure S8. Analysis of quiescence stimulation by PG tetra- and pentapeptides ......... 78 
MANUSCRIPT 2 
Figure 1. Growth inhibition of B. pumilus YP001 against (a) V. harveyi BB120 (b) V. 
parahaemolyticus PSU5429, (c) V. anguillarium NB10Sm, and (d) V. coralliitlycus 
RE22 after 24 h incubation on YP30 at 27 ºC. ......................................................... 115 
Figure 2. Swarming motility assay for B. pumilus YP001 plated in co-culture with V. 
parahaemolyticus PSU5429 at concentrations of (a) 1x105 CFU/mL, (b) 1x102 
CFU/mL, (c) 1x101 CFU/mL, and (d) no dilution. Plate imaged after 24 h incubation 
at 27 ºC. ..................................................................................................................... 116 
Figure 3. MALDI-IMS imaging shows the spatial distribution of compounds produced 
during chemical interaction of B. pumilus YP001 and V. parahaemolyticus PSU5429.
 ................................................................................................................................... 117 
  
 
xv
FIGURE                 PAGE 
Figure 4. Chemical structures of compounds 1 and 2. .............................................. 120 
Figure 5. 1H−1H COSY and key HMBC correlations for compound 1. ................... 121 
Figure 6. Swarming bioactivity in response to compound 3 at 10 µg (a), 100 µg (b) 
and compound 4 10 µg (c), and 100 µg (d) after 24 h incubation at 27 ºC on YP30 
agar. ........................................................................................................................... 122 
Figure 7. Effects of purified surfactin (20 µg/disk) and amicoumacin (20 µg/disk) (a), 
surfactin (20 µg/disk) only (b), amicoumacin (100 µg/disk) only (c) and B. pumilus 
YP001 colony (5 µL at 1x105 CFU/mL from a broth culture) (d) on V. 
parahaemolyticus PSU5429 after 24 h incubation at 27 ºC.. .................................... 123 
Figure S1. High resolution TOF-MS for 3 m/z 1034.6790 [M-H]- in negative ion 
mode. The declustering potential was set to -185 and collision energy to -33. ........ 124 
Figure S2. High resolution TOF-MS for 4 m/z 1048.7 [M-H]-  in negative ion mode. 
The declustering potential was set to -200 and collision energy to -50. ................... 125 
Figure S3. MADLI-TOF IMS total ion counts (TIC) taken after 48 h incubation 
indicating the production of pumilacidin B (m/z 1059 [M+Na]+), F/G (m/z 1073 
[M+Na]+), and E (m/z 1087 [M+Na]+). ..................................................................... 126 
Figure S4. Biosynthesis of amicoumacin by B. pumilus YP001 domain predictions 
carried out in Geneious ............................................................................................. 127 
Figure S5. Chemical isolation scheme for B. pumilus YP001 .................................. 132 
 
  
 
xvi
FIGURE                 PAGE 
Figure S6. Swarming assay for (a) lipoamide C (100 µg), and (b) lipoamide B2 (100 
µg) against V. parahaemolyticus PSU5429. ............................................................. 134 
Figure S7. MADLI-TOF IMS ionization of amicoumacin B m/z 425 [M+H]+ and 447 
[M+Na]+ plated at 10 mM in methanol onto a YP30 plate.  ..................................... 135 
Figure S8. Swarming assay for 100 µg of surfactin D (i) and C-15 (ii) against (a) 
Vibrio coralliilyticus RE22, (b) Vibrio harveyi BB120, (c) Vibrio anguillarum 
NB10Sm after 48 h incubation at 27 ºC. ................................................................... 136 
Figure S9. 1H-NMR spectrum (500 MHz, DMSO-d6) of compound 1 from B. pumilus 
YP001. ....................................................................................................................... 137 
Figure 10. 13C-NMR spectrum (500 MHz, DMSO-d6) of compound 1 from B. pumilus 
YP001. ....................................................................................................................... 138 
Figure S11. : 1H−1H COSY NMR spectrum (500 MHz, DMSO-d6) of compound 1 
from B. pumilus YP001. ............................................................................................ 139 
Figure S12. HSQC NMR spectrum (500 MHz, DMSO-d6) of compound 1 from B. 
pumilus YP001. ......................................................................................................... 140 
Figure S13. HMBC NMR spectrum (500 MHz, DMSO-d6) of compound 1 from B. 
pumilus YP001. ......................................................................................................... 141 
Figure S14. IR spectrum of compound 1.  ................................................................ 142 
Figure S15. HRESIMS of compound 1 measured in positive ion mode (m/z 351.2226 
[M+H]+ and 373.2048 [M+Na]+). ............................................................................. 143 
  
 
xvii
FIGURE                 PAGE 
Figure S16. Lipoamide C (2) IR data ........................................................................ 144 
Figure S17. HRESIMS of lipoamide C (2) recorded in positive ion mode (m/z 
345.1713 [M+H]+)..................................................................................................... 145 
Figure S18. 1H-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001. ......................................................................................................... 146 
Figure S19. 13C-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001. ......................................................................................................... 147 
Figure S20. gCOSY-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001. ......................................................................................................... 148 
Figure S21. TOCSY-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001. ......................................................................................................... 149 
Figure S22. HSQC-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001. ......................................................................................................... 150 
Figure S23. 1H-NMR spectrum (500 MHz, DMSO-d6) of surfactin C (3) from B. 
pumilus YP001. ......................................................................................................... 151 
Figure S24. 1H-NMR spectrum (500 MHz, DMSO-d6) of of AI-77-F from B. pumilus 
YP001.. ...................................................................................................................... 154 
APPENDIX A 
Figure 1. Peptidoglycan isolation scheme indicating bioassay guided fractionation of 
crude peptidoglycan digestion product from E. coli CFT073. .................................. 178 
  
 
xviii
FIGURE                 PAGE 
Figure 2. Isolation methods for peptidoglycan from E. coli CTF073 cells to produce 
‘crude’ peptidoglycan preparations used for testing in the quiescence bioassay  ..... 179 
Figure 3. Synthesis, recycling and catabolism pathways for peptidoglycan in the cell. 
Indicating transporters on the cellular membrane involved in uptake and regulation 
into the cell. All mutant knockout pathways target a different source of peptidoglycan 
transport..................................................................................................................... 180 
Figure 4. High resolution tandem mass spectrometry for disaccharide tetrapeptide 
(NAG-NAM-Ala-Glu-DAP-Ala) as a potential constituent of crude peptidoglycan 
preparations. Total ion counts (TIC) for crude peptidoglycan (a), extracted ion counts 
(XIC) for disaccharide tetrapeptide (b), and MS/MS fragmentation of disaccharide 
tetrapeptide mass to confirm its structure (c). ........................................................... 181 
Figure 5. High resolution tandem mass spectrometry for disaccharide tripeptide 
(NAG-NAM-Ala-Glu-DAP) as a potential constituent of crude peptidoglycan 
preparations. Total ion counts (TIC) for crude peptidoglycan (a), extracted ion counts 
(XIC) for disaccharide tripeptide (b), and MS/MS fragmentation of disaccharide 
tripeptide mass to confirm its structure (c). .............................................................. 182 
Figure 6. High resolution tandem mass spectrometry for disaccharide dipeptide (NAG-
NAM-Ala-Glu) as a potential constituent of crude peptidoglycan preparations. Total 
ion counts (TIC) for crude peptidoglycan (a), extracted ion counts (XIC) for 
disaccharide dipeptide (b), and MS/MS fragmentation of disaccharide dipeptide mass 
to confirm its structure (c). ........................................................................................ 183 
  
 
xix
FIGURE                 PAGE 
Figure 7. High resolution tandem mass spectrometry for pentapeptide (Ala-Glu-DAP-
Ala-Ala) as a potential constituent of crude peptidoglycan preparations. Total ion 
counts (TIC) for crude peptidoglycan (a), extracted ion counts (XIC) for pentapeptide 
(b). Ion abundance was too low to accurately assess the structure by MS/MS ........ 184 
Figure 8. High resolution tandem mass spectrometry for tetrapeptide (Ala-Glu-DAP-
Ala) as a potential constituent of crude peptidoglycan preparations. Total ion counts 
(TIC) for crude peptidoglycan (a), extracted ion counts (XIC) for tetrapeptide (b), and 
MS/MS fragmentation of tetrapeptide mass to confirm its structure (c). ................. 185 
Figure 9. High resolution tandem mass spectrometry for tripeptide (Ala-Glu-DAP) as 
a potential constituent of crude peptidoglycan preparations. Total ion counts (TIC) for 
crude peptidoglycan (a), extracted ion counts (XIC) for tripeptide (b). Ion abundance 
was too low to accurately assess the structure by MS/MS ....................................... 186 
APPENDIX B 
Figure 1. Overlaid chromatograms for SNP spiking experiment at doses 0, 1 and 10 
µM. (A) B. pumilus YP001, (B) Pseudoalteromonas sp. YPC21, (C) 
Pseudoalteromonas sp. YPC22, (D) L. maritime YPC210 (E) L. maritime YPC210   
 ................................................................................................................................... 198 
Figure 2. Assessment of growth for putative probiotics by absorbance of light 
wavelength (600 nm) as a proxy for cell density over time  ..................................... 199 
APPENDIX C 
  
 
xx
FIGURE                 PAGE 
Figure 1. NRPS biosynthetic gene cluster analysis and alignment to known gene 
clusters. Binding pocket sequence analysis was used to predict the substrate specificity
 ................................................................................................................................... 212 
Figure 2. Initial chemical screening, 96 well plate fractionation from crude extract to 
identify the peak responsible for the observed antibiotic activity. ........................... 213 
Figure 3. Large scale chemical isolation of agrobactin from a co-culture of Loktanella 
maritima YPC211 and Thalassobius sp. strain I31.1 ................................................ 214 
Figure 4. High resolution tandem mass spectrometry intensity from direct injection 
ESI in positive ion mode (declustering potential 150; collision energy 30) for 
agrobactin m/z 637.2566 [M+H]+, 659.2373 [M+Na]+, and 681.2185 [M+Fe]+. ..... 215 
Figure 5. Direct injection TOF MS/MS fragmentation positive ion mode of agrobactin 
m/z 637.2 [H+H]+ to produce identifiable building blocks and structure confirmation 
 ................................................................................................................................... 216 
Figure 6. Proton NMR spectrum of agrobactin Varian NMR 500 MHz with DMSO-
d6 as the solvent at 25 oC ........................................................................................... 217 
Figure 7. Analytical HPLC chromatogram of agrobactin as purified product .......... 218 
 
 
 
 
  
 
xxi
FIGURE                 PAGE 
Figure 8. Disc diffusion assay indicating that only crude extracts from co-cultures of 
Thalassobius I31.1 and L. maritima YPC211 are  able to elicit an antibiotic effect 
against V. anguillarum NB10Sm. Positive control is ciprofloxacin, negative controls 
are crude media extract and methanol blank. Testing monoculture extracts of 
Thalassobius I31.1 and L. maritima YPC211 ........................................................... 219 
Figure 9. MIC assay for agrobactin against MRSA plotted as averages and standard 
deviation * P<0.05 ** P<0.01 from agrobactin (methanol) and ciprofloxacin (DMSO). 
Cell density measured by optical density (600 nm absorbance). .............................. 220 
  
 
1
CHAPTER 1 
 
INTRODUCTION 
 
1.1 Bacterial signaling and infections 
Molecular signaling occurs across every known life form ensuring coordinated 
behaviors for cells and organisms. In eukaryotes, chemical cues may be exchanged in 
the form of hormones whereas prokaryotes are well known to utilize a phenomenon 
called quorum sensing. Quorum sensing is a defined mechanism of chemical 
communication facilitating coordinated behaviors akin to those of multicellular 
organisms (1).  
In bacteria, cell-cell communication facilitates key processes such as 
bioluminescence, the secretion of virulence factors key for disease states, production 
of secondary metabolites, reduction of metabolic activity and the formation of 
biofilms (2-4). All of these are energetically costly and ineffective strategies for an 
individual cell, but become extremely advantageous when undertaken by a population. 
How individuals correctly interpret the blend of signals in their vicinity to 
appropriately regulate their gene expression is crucial to their survival and success. 
Chemical relationships between all organisms have been co-evolving over 
billions of years. As bacteria move through their environments, they also encounter 
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and respond to complex mixtures of molecules produced by other organisms including 
competitors. These foreign compounds can also influence gene expression or have 
toxic consequences. Many of these molecules secreted by bacteria can act on diverse 
cell types, even altering cell functions of eukaryotic cells (5). These inter-kingdom 
communications mediate symbiotic and pathogenic relationships between bacteria and 
their animal and plant hosts (6). Understanding the roles that specific compounds play 
in natural environments can inform new ways of controlling bacterial populations, 
especially for infections. This dissertation aims to expand our understanding of 
chemical signaling to facilitate new treatment strategies for bacterial infections. 
 
1.2 Quorum sensing, N-acyl homoserine lactones and quiescence 
Quorum sensing is the underlying communication pathway that controls density 
dependent decision-making in prokaryotes. Individual cells produce and excrete signal 
molecules that can be detected by their kin. The concentration of these signal 
molecules, referred to as autoinducers, increases until a receptor response is initiated 
within the population (2). Hence, this phenomenon relies upon the abundance of 
extracellular compounds as a proxy for cell abundance, and enables coordinated, 
multi-cellular behaviors by bacteria.  
One of the largest classes of autoinducers are N-acyl homoserine lactones 
(AHLs). These molecules are produced prolifically across phylogenetically-diverse 
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Gram-negative bacteria and are able to freely diffuse across bacterial membranes 
making them ideal cell-cell signaling molecules. When AHLs accumulate above the 
required threshold, the autoinducers bind to a receptor and trigger a signaling cascade 
that results in population-wide alterations in gene expression (7).  Quorum sensing has 
been shown to control virulence factor production and biofilm formation during 
infections (2). Virulence factors often trigger the signs of infection in the host 
organism. While AHLs have been extensively studied in Gram-negative bacteria, the 
chemical diversity of quorum sensing signals remains unknown. Understanding the 
identity and roles of autoinducers is important for finding new strategies and 
treatments for bacterial infections (8). 
In Chapter 2 of this dissertation, I explored the use of peptidoglycan fragments as 
chemical signals to reverse dormant phenotypes in uropathogenic Escherichia coli 
(UPEC).   Some pathogens, including E. coli, rely upon dormant (i.e. non-
proliferating) states to persist within hosts. Growing cells release ~7% peptidoglycan 
(PG) fragments from their cell wall during exponential growth (9). These fragments 
have been shown to be key signals for reversing dormancy in Bacillus and 
Mycobacterium (2,10). Hence, certain PG fragments may serve as quorum signals to 
indicate favorable conditions and exit this state, leading to recurrent infections of the 
host (11).  
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The mechanisms and requirements for dormancy (i.e. quiescence) in UPEC and 
the sensing molecules that reverse this phenotype are now becoming better 
understood.   UPEC cells are able to adhere to human bladder epithelial cells, where 
they are internalized to form intracellular bacteria communities (IBCs). Once 
internalized, UPEC cells enter into a quiescent state, during which they evade both 
host immune response and antibiotic treatment (12). The phenomenon of quiescence 
has been reported for several bacteria including Bacillus spp., Bordetella pertusis, and 
E. coli (3,12). For certain UPEC, the quiescent state can be reliably simulated through 
agar based nutrient limitation (12).  
The archetypical peptidoglycan structure consists of a repeating disaccharides (N-
acetylglucosamine and N-acetylmuramic acid) backbone covalently bonded to a stem 
peptide chain containing 2-5 amino acid residues. The stem peptide structure is 
predominantly L-alanine, D-glutamic acid, meso-diaminopimelic acid (mDAP) and D-
alanine. The dibasic amino acid DAP forms crosslinks with adjacent strands forming 
the structural rigidity of the cell wall (Figure 2). Bacterial peptidoglycan structure 
variability is extensive, including modifications of both the sugar backbone and amino 
acid stem peptide chain (13). For example, Staphylococcus peptidoglycan exhibits a 
modification of L-lysine at the third position of the stem peptide chain (14). Most 
Gram-positive bacteria contain a deacetylase, encoded by the gene pdgA, which causes 
N-deacetylation of either one or both of the sugars in the backbone (14). Many studies 
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have investigated the properties of peptidoglycan fragments; however, very few have 
been able to deduce the single bioactive components.  
Components of peptidoglycan have been investigated for their function in 
modulating developmental transitions out of non-growing, dormant cell states and for 
their effects on host cells during infections. Peptidoglycan has been shown to stimulate 
resuscitation and germination of Mycobacterium tuberculosis, Mycobacterium 
smegmatis and Bacillus subtilis (10, 15, 16). Hosts cell interactions with 
peptidoglycan fragments vary from symbiotic to pathogenic. In whooping cough, the 
anhydrous disaccharide tetrapeptide of peptidoglycan (TCT) causes tracheal 
cytotoxicity to human ciliated epithelial cells (17, 18). Smaller fragments of the stem 
peptide structure also elicit similar dose dependent toxicity (17). The same product 
from Neisseria gonorrhoeae is cytotoxic to human fallopian tube epithelial cells (19, 
20). Contrastingly, Vibrio fischeri utilizes TCT to induce normal cell metamorphosis 
in the light organ of bobtail squid forming a mutualistic relationship (21, 22).  
Peptidoglycan-derived fragments are recognized by host immune systems and 
promote defense responses against bacterial infections in mammals, invertebrates and 
plants (5, 17, 23). Thus, peptidoglycan can serve as an inter-kingdom signal molecule, 
modulating both prokaryotic and eukaryotic cells. Table 1 summarizes the known 
functions of common peptidoglycan fragments. Interestingly, most studies are unable 
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to identify the specific PG fragments that are singly responsible for the observed 
effects. 
Although mostly bacterial pathogens have been studied in their ability to form a 
dormant state, about 60% of the microbial biomass on Earth is thought to be quiescent 
(11). These organisms may survive in the absence of nutrients for periods of up to 
years. Creating robust in vitro assays to demonstrate and study quiescence are 
inherently difficult, but essential for understanding the control mechanisms for 
reversing these states (7). The occurrence and signaling mechanisms that facilitate the 
behavior into and out of bacterial quiescence are currently understudied and represent 
an important area of research for tackling recurrent bacterial infections.  
 
1.3 Natural products and bacterial signaling 
Natural products have historically served as a powerful source of novel 
therapeutic agents against bacterial infections. Currently, 59% of all FDA approved 
drugs to treat bacterial infections originated from natural products produced by 
microorganisms (24). Traditionally these molecules are isolated and tested as pure 
compounds in bioassays. However, in natural environments many signals are being 
produced concurrently and may work cooperatively. This creates a complex interplay 
that is likely important for microbial competition and disease progression but poorly 
understood. Replicating the ‘cocktails’ of compounds used in nature represents an 
  
 
7
untapped opportunity to design of new therapeutic drugs and drug combinations. This 
is especially true as new knowledge emerges regarding phenotypes that influence drug 
resistance and genomic technologies enable more rapid discovery of novel natural 
products skeletons. 
Vibrio spp. are ubiquitous in marine ecosystems and prolific pathogens. For 
example, V. parahaemolyticus is the leading cause of seafood-borne illness in the 
United States (29), causing gastroenteritis that often requires treatment with 
antibiotics. Natural products produced by marine bacteria may offer novel ways of 
tackling the prevalence of this bacterium in seafood. Swarming motility is one 
phenotype that increases antibiotic resistance and speed of infection on solid or semi-
solid surfaces such as tissues (25, 26). Bacterial swarming is induced by quorum 
sensing, alterations in ion channel fluxes, and iron scarcity (27). Swarming is enabled 
by molecules that decrease surface tension, thereby allowing coordinated, directional 
movement of cells (27, 28). Identification of molecules that induce or inhibit 
swarming motility could lead to unconventional tools for controlling infections. 
The ubiquitous Gram-positive marine bacterium Bacillus pumilus produces 
structurally diverse secondary metabolites including lipopeptide, polypeptides, 
macrolactones, fatty acids, polyketides and isocoumarins (30-32).  As explored in 
Chapter 3 of this dissertation, partnering antimicrobial activity with induction of 
bacterial motility poses an unconventional and intriguing approach for controlling and 
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modulating infections. These ecological observations could unlock further research on 
combinations of secondary metabolites as multifaceted treatment strategies. 
 
1.4 Emerging techniques for understanding the roll of cell signaling molecule 
bacterial diseases. 
Antibiotic resistant bacterial infections pose a world health threat, causing more 
than two million illnesses in the USA in 2014 (33). The increased prevalence of multi-
drug-resistant (MDR) pathogens has caused decreased effectiveness of front line 
antibiotics. In the United States alone, 23,000 people die annually from drug-resistant 
infections (34). Despite incentives from the Infectious Disease Society of America 
(IDSA), approval of new antibiotics has dropped significantly in recent years and only 
four novel drugs have been approved since 1998 (35). Alternative treatment options 
are needed to increase the effectiveness of our current antibiotics while avoiding the 
emergence of drug resistance. Such options could include compounds that modulate 
crucial bacterial behaviors involved in pathogenesis.  
 
1.4.1 Matrix-assisted laser desorption ionization-time of flight imaging mass 
spectrometry (MALDI-TOF IMS) 
Mass spectrometry is an analytical technique utilized to understand the chemical 
diversity of the natural world. It is highly sensitive and has allowed significant 
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advances in the detection of naturally occurring molecules and measurement of their 
ecologically relevant concentrations. The development of imaging mass spectrometry 
(IMS) techniques has advanced this approach to include spatial mapping of ionizable 
molecules on a surface.  IMS is now particularly useful for probing the biological 
effects induced by signaling molecules (36). 
Visualizing chemical production in situ is fundamental to understanding the direct 
relationships between signal molecules, allelopathic secondary metabolites and 
bacterial response. Matrix-Assisted Laser Desorption Ionization-Time of flight 
Imaging Mass Spectrometry (MALDI-TOF IMS) allows in situ data collection for 
compounds produced by actively growing bacterial colonies on agar surfaces. This 
technique involves culturing one or more bacteria on thin agar plates and applying a 
uniform dry coat matrix. The matrix is generally a combination of small organic acids 
that co-crystalize with the sample and facilitate ionization from laser energy. MALDI-
TOF IMS is able to capture the metabolic exchange of information between two 
bacteria grown in close proximity (37). This powerful technique can be applied to 
rapidly discriminate bacterial function based on key metabolite production (38). 
MADLI-TOF IMS was used in Chapter 3 of this dissertation to investigate the 
chemical interplay between a marine B. pumilus and V. parahaemolyticus.  
 
1.4.2 Genomic and computational approaches for natural product discovery 
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Advances in genomics have revealed that the majority of biosynthetic gene 
clusters (BGCs) are not linked to any previously identified natural products (39). The 
abundance of ‘silent’ BGCs within even well studied bacteria has identified a 
bottleneck for natural product discovery (40). Genomic data also provides substantial 
insights into the pool of secondary metabolites that individual bacteria strains are able 
to produce. Several powerful online tools now provide structure predictions of 
biosynthetic products from sequence data (41), allowing targeting of novel natural 
product scaffolds from genetically unique pathways. These chemical pathways are 
frequently not activated under standard laboratory conditions but may be induced 
during co-culturing conditions due to competitive conditions that better mimic the 
natural environment. Chapter 4 of this dissertation, includes a collection of three 
manuscripts describing the genomes of marine bacteria and their expected biosynthetic 
potential. 
 
1.5 Future perspectives for bacterial disease treatment 
In nature, diverse microbes are in intimate contact with each other, and cell-cell 
chemical signals are exchanged within and between phylogenetically distinct 
populations (42). These signals can range from simple lactones to complex peptides. 
Each individual compound can alter the expression of vast numbers of genes, affecting 
biological processes and bacterial infections. Interrupting these signals may block 
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virulence factors responsible for antibiotic-resistance-increasing phenotypes without 
increasing MDR, thus offering possible advantages for treating bacterial infections. 
Alternative treatment options for bacterial infections, including those that increase the 
effectiveness of our current antibiotics, may someday significantly improve our ability 
to confront drug resistance. The overall theme of my dissertation research has been to 
explore how bacterial metabolites influence the behaviors and growth of two 
problematic pathogens: human UPEC and the marine pathogen V. parahaemolyticus. 
The aim was to reveal possible new mechanisms and tools to tackle these infectious 
diseases. 
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Figure 1: Model of bacterial chemical communication. Chemical signals, in the form 
of quorum sensing autoinducers and secondary metabolites, act as inter and intra-
species communications to facilitate phenotypic changes. 
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Figure 2: The structure of peptidoglycan. A) A single muropeptide disaccharide 
pentapeptide. B) The structure of peptidoglycan within the cell wall showing the 
dibasic amino acid cross-link between strands that forms the structure rigidity.  
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Table 1: Known chemical signaling functions of compounds from peptidoglycan. 
Peptidoglycan Fragment Structure Producing Organism Function 
Disaccharide tripeptide 
 
E. coli and B. subtilis 
 
Exit from dormancy in B. subtilis 
(3). 
Anhydro-disaccharide 
tetrapeptide 
 
B. pertussis 
 
V. fischeri 
 
N. gonorrheae 
Tracheal cytotoxicity to human 
ciliated cells (17). 
Signal for morphogenesis in the 
bobtail squid (21). 
Cytotoxic to human fallopian tube 
epithelial cells (19). 
Disaccharide 
pentapeptide 
 
Aeromonas spp. Beta-lactamase induction in 
Aeromonas hydrophila (43). 
Anhydro-disaccharide 
pentapeptide 
 
E. coli Beta-lactamase induction in 
Enterobacter cloacae (44). 
Lac-tetrapeptide 
 
B. pertussis 
 
Tracheal cytotoxicity to human 
ciliated cells (17). 
 
L-ala
D-glu
mDAP
L-ala
D-glu
mDAP
D-ala
O
L-ala
D-glu
mDAP
D-ala
D-ala
L-ala
D-glu
mDAP
D-ala
D-ala
O
L-ala
D-glu
mDAP
D-ala
D-lactate
  
 
22
Tetrapeptide 
 
B. pertussis 
 
Partial tracheal cytotoxicity to 
human ciliated cells (17). 
 
Dipeptide 
 
B. subtilis/pDML995 Increased beta-lactam resistance in 
Bacillus licheniformis (45). 
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Abstract  
Uropathogenic Escherichia coli (UPEC) are the leading cause of human urinary tract 
infections (UTIs) and many patients experience recurrent infection after successful 
antibiotic treatment. The source of recurrent infections may be persistent bacterial 
reservoirs in vivo that are in a quiescent state and thus are not susceptible to 
antibiotics. Here, we show that multiple UPEC strains require a quorum to proliferate 
in vitro with glucose as the carbon source. At low cell density, the bacteria remain 
viable but enter a quiescent, non-proliferative state. Of the clinical UPEC isolates 
tested to date, 35% (51/145) enter this quiescent state, including isolates from the 
recently emerged, multidrug-resistant pandemic lineage ST131 (i.e., strain JJ1886) and 
isolates from the classic endemic lineage ST73 (i.e., strain CFT073). Moreover, 
quorum-dependent UPEC quiescence is prevented and reversed by small molecule 
proliferants that stimulate growth, including peptidoglycan (PG) stem tetra- and 
pentapeptides, and the amino acids L-lysine and L-methionine. Peptidoglycan 
fragments originate from the peptidoglycan layer that supports the bacterial cell wall 
but are released as bacteria grow. These fragments are detected by a variety of 
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organisms, including human cells, other diverse bacteria and, as we show here for the 
first time, UPEC. Together, these results show that (i) PG stem peptide sensing and 
uptake of L-lysine by UPEC modulate the quorum-regulated decision to proliferate, 
and (ii) UPEC quiescence can be prevented by both intra- and interspecies PG 
fragment signaling. 
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Introduction  
At least 80% of urinary tract infections (UTIs) are caused by uropathogenic 
Escherichia coli (UPEC) strains, and 27% of patients with a UTI experience 
recurrence within 12 months after successful antibiotic treatment 1-3. UPEC appear to 
enter a quiescent, non-growing state within urothelial transitional cells in the bladder 
wall that may enable E. coli, long after antibiotic treatment has been terminated, to 
resume division within bladder urine after apoptotic release from those cells 4,5.  
We recently reported the discovery of a quiescent state of E. coli that is 
common among UPEC strains 6. E. coli CFT073, a member of the major UPEC 
lineage sequence-type (ST) 73, and approximately 80% of ST73 strains tested, 
proliferate on glucose minimal agar plates seeded with 106 or more CFU, but become 
quiescent on glucose minimal agar when plated at a cell density of less than 106 CFU 
6. Moreover, 23% of randomly selected UPEC strains of diverse STs isolated from 
community-acquired UTIs also become quiescent on glucose minimal plates seeded 
with  less than 106 CFU 6. Remarkably, these results indicate that growth of many 
UPEC strains on glucose minimal agar is quorum-dependent 6. Alternative sole 
carbon sources, including acetate, arabinose and N-acetylglucosamine (NAG), also 
lead to cells entering quiescence at low plating density, whereas glycerol, ribose and 
xylose support proliferation 6. We also reported that mini-Tn5 transposon insertions in 
five central carbon metabolism genes (gdhA, gnd, pykF, sdhA, zwf) prevent 
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quiescence, suggesting that metabolic function must remain intact during quiescence 
even though the cells are non-proliferative. CFT073 quiescence is also prevented 
when cells are placed near a single colony of actively growing CFT073 or E. coli 
MG1655, a K-12 laboratory strain, suggesting that the actively growing cells release 
one or more molecules that act as a proliferant 6. Indeed, we showed that L-lysine is a 
proliferant for quiescent CFT073 cells, but only in combination with either L-
methionine or L-tyrosine, yet CFT073 is not auxotrophic for lysine, methionine or 
tyrosine, and the remaining 17 amino acids play no role in preventing CFT073 
quiescence 6. Quorum-dependent proliferation suggests the ability to sense a cell-to-
cell signal(s). In this case the signal includes L-lysine and L-methionine, and signal 
detection underlies the decision by each individual cell to grow and divide or to enter 
the quiescent state. This suggests that the transition between the proliferative and 
quiescent states is controlled by a quorum sensing system 7,8.  
Here we show that quiescent CFT073 cells are filamentous and that L-lysine 
import into quiescent CFT073 stimulates proliferation, suggesting that L-lysine 
synthesis is inhibited during quiescence. In two pathogenic UPEC strains, including 
CFT073, a prototypic ST73 UPEC strain, and JJ1886, a pandemic ST131 strain that 
displays increased sensitivity to proliferants, we show that peptidoglycan (PG) stem 
peptides prevent quiescence. PG is a component of the bacterial cell wall that contains 
polymers of alternating linked sugars NAG and N-acetyl muramic acid (NAM), with 
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attached stem peptides containing D-amino acids that crosslink. PG fragments have 
been reported to regulate development of Bacillus subtilis and Mycobacterium 
tuberculosis 9-11. PG fragments are also normally secreted by growing E. coli 12, and 
here we show for the first time that they act as quorum-signaling molecules in UPEC. 
In this study we demonstrate that population-sensing and metabolite availability 
modulate the quiescent state of UPEC, and we define an in vitro model system for 
UPEC quiescence for further study of UPEC physiology.  
 
Results 
Quorum-dependent growth of UPEC and prevention of quiescence on glucose 
minimal agar plates by secreted signals. UPEC strain CFT073 enters a quiescent 
state when plated at low cell density (<106 cells per plate) on glucose minimal agar yet 
grows robustly when plated at high cell density (>106 cells per plate), demonstrating 
that growth of CFT073 on glucose minimal agar plates is quorum-dependent (Fig. 
S1A). As reported previously, quiescent CFT073 cells can be resuscitated by 
challenge with specific external stimuli, called proliferants, including 5 µl of a 
solution containing L-lysine (1 mM) and L-methionine (1 mM), 5 µl of human urine, 
or a single colony of actively growing E. coli spp. (CFT073 or MG1655), added to the 
plate 6. In a soft agar overlay containing 104 quiescent CFT073 cells, we tested the 
known proliferants and in each case observed the development of a zone of actively 
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growing colonies surrounding the site of challenge (Fig. 1A). Without challenge, cells 
failed to grow throughout the course of the experiment (24 h) and remained quiescent. 
We also tested additional clinical isolates and found that quorum-dependent growth on 
glucose minimal agar is common among the ST131 UPEC strains in this study (8/33) 
(Table 1); however, we discovered that the number of cells constituting a quorum 
varies among strains. For example, the ST131 strain JJ1886 was proliferative on 
glucose minimal agar at a plating density greater than 103 CFU, but quiescent at or 
below 103 CFU (Table 1). Of the 35 strains tested in this study, 10 were reversibly 
quiescent on glucose minimal agar, and three of those strains were quiescent at or 
below a plating density of 103 CFU, but non-quiescent at 105 CFU (Table 1). These 
results show that sensitivity for quorum detection varies by strain, i.e., is strain-
specific. 
 
Next, we monitored the zone of growth of CFT073 cells as they exited quiescence 
over 72 h. First, we poured soft agar plates containing quiescent CFT073 cells seeded 
at 104 CFU per plate, placed an actively growing colony of CFT073 onto the surface 
of each plate by toothpick and measured the zones of growth around the sites of 
inoculation at 24, 48 and 72 h. We observed that the zone of growth expands in 
diameter until the entire plate is covered by a lawn of actively growing cells (Fig. 1B 
and 1C). There are two potential scenarios to explain this result. First, the 
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proliferant(s) that stimulates growth of quiescent cells is continuously released from 
the toothpicked colony throughout the experiment and induces growth of distal 
quiescent cells as it diffuses across the plate. Alternatively, the proliferant(s) that 
stimulates growth of quiescent cells is released from the toothpicked colony but, upon 
release of the signal, neighboring and formerly quiescent cells begin secreting their 
own signal, thereby stimulating adjacent quiescent cells to grow. To distinguish 
between these possibilities, glucose minimal agar plates were seeded with 104 
quiescent CFT073 cells from a stationary phase liquid glucose minimal medium 
culture, and a single CFT073 colony was toothpicked onto the center of each plate. 
The plates were then incubated for 24 h. During that time, a small zone of growth 
formed on each plate around the central toothpicked colony (Fig. 1B, 1C and 1D). 
After the zone had formed at 24 h, the toothpicked colony was removed to stop the 
colony from secreting additional signal(s). Even after removal of the toothpicked 
colony from the plate, the zone of growth continued to expand, unabated, for an 
additional 48 h and at a similar rate as the control plate, where the colony had been left 
intact (Fig. 1C and 1D). These results suggest that the proliferation-promoting signal 
propagates across the plate from CFT073 cells as they exit quiescence. These results 
further show that quiescent CFT073 cells at the edge of the plate remain viable and 
can be stimulated to proliferate for up to 72 h. 
 
  
 
32
Quiescent CFT073 cells are filamentous on glucose minimal agar plates. During 
infection, UPEC cells from quiescent intracellular reservoirs (QIRs) display several 
different morphologies, including rods, spheres and filaments 13-15. To determine if 
quiescent cells in our in vitro quiescence system also display morphological features 
that are distinct from actively growing cells, we compared the cell morphologies of 
CFT073 cells under several culture conditions, including LB agar, and glucose 
minimal agar supplemented with L-lysine (1 mM) and L-methionine (1 mM), where 
indicated (Fig. 2A). After 24 h on LB agar or on glucose minimal agar supplemented 
with L-lysine and L-methionine, colonies were apparent and individual cells collected 
and analyzed by microscopy appeared as short rods with mean lengths of 1.72 ± 0.59 
μm (n = 200) and 2.33 ± 0.80 μm (n = 200), respectively (Fig. 2A and 2B). By 
contrast, after 24 h on non-supplemented glucose minimal agar plates, no colonies 
were detected and quiescent cells harvested from the plate had a broad length 
distribution, with a mean length of 7.17 ± 4.34 μm (n = 200), which is 300% longer 
than cells grown on glucose minimal agar supplemented with lysine and methionine 
(Fig. 2A and 2B).  Many quiescent cells were longer than 10 μm and 16.5% of them 
appeared to contain one or more incomplete septa (Fig. 2A and 2B) (Fig. S1B). To 
assess for changes in cell length with extended incubation, we also measured cell 
length at 0 h and 48 h after entry into quiescence. At 0 h, cells harvested from a 
stationary phase culture grown in liquid glucose minimal medium were short rods with 
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a mean length of 2.14 ± 0.58 μm (n = 200). After 48 h on glucose minimal agar plates, 
quiescent cells were filamentous, with a mean length of 6.84 ± 3.76 μm (n = 72), 
which is similar to the mean length at 24 h (Fig. S1B and S1C).   These results suggest 
that quiescent CFT073 cells elongate during the first 24 h on the plate but fail to 
complete division.   
 
Lysine import is necessary for lysine to prevent quiescence, but an additional 
signal that induces proliferation is released from actively growing cells. L-lysine is 
a proliferant for quiescent CFT073 cells on glucose minimal agar in the presence of L-
methionine 6. To determine whether L-lysine must be imported into CFT073 cells to 
prevent quiescence, we constructed a CFT073 lysP insertion-deletion mutant by λ-Red 
recombination (Table S1). Of the three known lysine importers in E. coli, LysP is the 
major importer and a member of the amino acid, polyamine and organocation (APC) 
family of transporters 16,17_ENREF_9. CFT073 ∆lysP cells grew well overnight in 
liquid glucose minimal medium, similar to the wild type CFT073 strain (Fig. S2A) 
and exhibited quiescence on glucose minimal agar at low cell density (104 cells per 
plate) (Fig. 3); yet, it grew robustly when plated at high density (108 cells per plate). 
Unlike wildtype CFT073, when 5 µl of a solution of L-lysine (1 mM) and L-
methionine (1 mM) was added to quiescent CFT073 ∆lysP cells plated at 104 CFU, no 
colony growth was observed after 24 h of incubation, suggesting that LysP-dependent 
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transport is critical for lysine to stimulate proliferation. This also suggests that lysine 
biosynthesis is inhibited in quiescent cells. CFT073 ∆lysP was complemented with a 
plasmid containing lysP (pLysP), which restored the ability of the strain to proliferate 
upon addition of L-lysine in the presence of L-methionine at low cell density (Fig. 3). 
Although quiescent CFT073 ∆lysP cells failed to respond to L-lysine, they proliferated 
after a colony of actively growing CFT073 cells was added to the plate (Fig. 3). 
Collectively, these results suggest that import of L-lysine is required for L-lysine to 
stimulate proliferation and override the absence of the quorum, and that one or more 
L-lysine-independent proliferants that reverse quiescence are secreted from bacterial 
colonies.   
 
ArgP is a transcriptional regulator of lysP 16,18. In the absence of lysine, ArgP 
positively regulates transcription of lysP, along with several E. coli genes involved in 
lysine and PG biosynthesis, including dapB (dihydropicolinate reductase), dapD 
(tetrahydrodipicolinate succinylase), lysA (diaminopimelate decarboxylase) and lysC 
(aspartokinase III) 16,18-20. To test whether ArgP plays a regulatory role in quorum-
dependent growth or quiescence, we deleted argP. Like wild type CFT073, CFT073 
ΔargP cells grew well overnight in liquid glucose minimal medium (Fig. S2A) and 
were quiescent at low cell density (104 CFU per plate) on glucose minimal agar (Fig. 
3), indicating that ArgP is not essential for inducing quiescence at low density (Fig. 3). 
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Similar to the result with CFT073 ∆lysP cells, quiescent CFT073 ΔargP cells failed to 
respond to the addition of L-lysine with L-methionine after 24 h of incubation, but the 
cells proliferated in response to a colony of CFT073 toothpicked to the center of a 
glucose minimal agar plate seeded with 104 CFU of CFT073 ΔargP (Fig. 3). 
Complementation of CFT073 ∆argP with the wildtype CFT073 argP gene on a 
plasmid (pArgP) restored the ability of the strain to respond to L-lysine in the presence 
of L-methionine at low cell density (Fig. 3). Since LysP expression has been reported 
to be repressed 35-fold in E. coli argP mutants 20, this result both (i) supports the 
conclusion that external L-lysine must be transported into CFT073 via LysP in order 
to prevent quiescence and (ii) confirms that expression of LysP is regulated by ArgP. 
Together, these results also show that there is a molecule(s) other than L-lysine 
secreted by actively growing cells that stimulates proliferation of quiescent CFT073 
cells. 
 
To further clarify why the population threshold that defines a quorum varies between 
strains, we investigated the ST131 clinical isolate JJ1886, which exhibits quiescence 
on glucose minimal agar at or below a plating density of 103 CFU, but grows robustly 
on such plates at 105 CFU and in liquid glucose minimal medium (Fig. 4A and S2B). 
We observed that 5 µl of a solution of L-lysine (1 mM) alone is sufficient to promote 
growth and prevent quiescence of JJ1886 plated at low density on glucose minimal 
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agar (103 CFU per plate), although growth is more efficient in the presence of L-
methionine (1 mM), and L-methionine (1 mM) alone does not stimulate growth (Fig. 
4B). Since quiescent JJ1886 cells on glucose minimal agar proliferate in the presence 
of L-lysine alone, we titrated the L-lysine concentration to determine the threshold for 
stimulation of growth and compared JJ1886 to CFT073. We determined that a low 
concentration of L-lysine (5 µl of 0.1 mM) is sufficient to promote proliferation of 
quiescent JJ1886 cells (103 CFU/plate), whereas quiescent CFT073 cells (103 
CFU/plate) proliferated at a higher concentration of L-lysine (>0.5 mM) and only in 
the presence of L-methionine. These results suggest that although JJ1886 behaves 
phenotypically similar to CFT073 with respect to quiescence, it is more sensitive to 
detecting or responding to an external signal(s) that prevents quiescence. We then 
tested if quiescent JJ1886 also responds to the other known CFT073 proliferants, 
including 5 µl of urine or a colony of actively growing E. coli cells, and observed that 
both agents were effective for stimulating proliferation of quiescent JJ1886 cells (Fig. 
4B).   
 
Since L-lysine stimulates proliferation of both JJ1886 and CFT073, we tested 5 µl of 
D-lysine (1 mM) and 5 µl of the biosynthetic lysine precursor diaminopimelic acid 
(Dap) (1 mM) for stimulating proliferation of quiescent cells. Both agents failed to 
stimulate growth of quiescent CFT073 and JJ1886 (Fig. S3A and S3B).  
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Peptidoglycan fragments prevent UPEC quiescence.  Next, we considered PG as a 
potential signal that would communicate a quorum since PG fragments, including di-, 
tri-, and tetrapeptides, are normally secreted by actively growing bacterial cells 
including E. coli 10,12,21,22. We tested if peptidoglycan fragments from E. coli could 
prevent quiescence and stimulate proliferation of CFT073 and JJ1886. Peptidoglycan 
was digested with mutanolysin, a mixture of two N-acetylmuramidases and an N-
acetylmuramyl-L-alanine amidase, to release a heterogeneous mixture of 
peptidoglycan fragments, including various muropeptides and stem peptides (Fig. 5A). 
Addition of the total mixture of digested peptidoglycan fragments from E. coli induced 
proliferation of quiescent JJ1886 cells, plated at 103 CFU per plate (Fig. 5A), and 
quiescent CFT073 cells, plated at 104 CFU per plate (Fig. S4A). Titrating the amount 
of total peptidoglycan added to the agar plate revealed a dose-dependent response, 
leading to differences in the zones of growth around the site of addition (Fig. S4B). 
Digested peptidoglycan from B. subtilis and Staphylococcus aureus also stimulated 
proliferation of quiescent JJ1886 and CFT073 cells (Fig. S4C and S4D). Furthermore, 
peptidoglycan fragments were also effective for stimulating proliferation of quiescent 
CFT073 lysP cells to proliferate, indicating that the peptidoglycan response is 
independent of lysine import (Fig. S5A).  Interestingly, these results show that 
quiescent E. coli cells respond to PG fragments from various bacterial species, which 
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can differ in the identity of the amino acid at the third position of the stem peptide, 
usually meso-Dap (i.e., E. coli) or L-lysine (i.e., S. aureus) 10,23,24.  
 
Peptidoglycan stem peptides act as signals to promote proliferation of quiescent 
JJ1886 and CFT073 cells. To identify which fragment(s) of digested PG stimulates 
proliferation of quiescent cells, we performed high performance liquid 
chromatography-mass spectrometry (HPLC-MS) on E. coli PG fragment mixtures 
(Fig. 5A) and tested fractions across the elution for the ability to promote proliferation 
of quiescent JJ1886 cells. We found that early fractions that were collected with 
retention times up to 10 min were sufficient to stimulate proliferation of quiescent 
JJ1886 cells (Fig. S5B). Tandem mass spectrometry confirmed that these fractions 
contain low molecular weight peptidoglycan fragments, consistent with stem peptides, 
such as the tri- and tetrapeptides. In contrast, later eluting fractions containing 
muropeptides did not stimulate proliferation of quiescent JJ1886 cells (Fig. S5B). 
 
To further explore the molecular determinants of PG peptides that stimulate 
proliferation of quiescent cells, we compared several high-purity stem peptide 
fragments of varying amino acid compositions and lengths. We observed that a 
tripeptide, representing the minimal unit of an E. coli peptidoglycan stem peptide that 
could be generated from amidase and carboxypeptidase activities in the E. coli 
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periplasm (L-Ala-D-Glu-mDap), failed to stimulate proliferation of quiescent JJ1886 
cells (Fig. 5B). However, a peptidoglycan pentapeptide, L-Ala-D-Glu-L-Lys-D-Ala-
D-Ala (A-E-K-A-A), similar to the stem pentapeptide present in S. aureus 
peptidoglycan, stimulated proliferation of quiescent JJ1886 (Fig. 5C) and CFT073 
(Fig. S5A) cells. We also tested a smaller fragment of the pentapeptide, acetyl-L-Lys-
D-Ala-D-Ala (K-A-A) but did not observe stimulatory activity (Fig. S6A). Fragments 
including the disaccharide moiety alone, containing NAG and NAM (NAG-NAM) 
(Fig. 5D), and higher molecular weight molecules with the attached stem peptide (i.e., 
disaccharide tetrapeptide) (Fig. 5E), in various states of crosslinking, eluted later, after 
10 min (Fig. S7), and had no proliferant activity. NAG-NAG, NAG and NAM were 
also tested, but none of these sugars stimulated proliferation of quiescent cells (Fig. 
S6B).  
 
To determine if a peptidoglycan stem peptide longer than three amino acids and 
derived from E. coli stimulates proliferation of quiescent cells, we generated 
tetrapeptide in situ by digesting purified disaccharide tetrapeptide (isolated by HPLC) 
with AmiD, an amidase from E. coli  22. AmiD cleaves a stem peptide from attached 
sugars (Fig. S8A). After cleavage to release the tetrapeptide, the reaction products 
were highly active for stimulating proliferation of both quiescent JJ1886 cells (Fig. 
5F) (Fig. S8B) and quiescent CFT073 cells (Fig. S8C). NAG-NAM displays no 
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activity alone, therefore these results suggest that peptidoglycan stem peptides from E. 
coli (tetrapeptide) and S. aureus (pentapeptide) function as proliferants. 
 
Finally, to further clarify if stem peptides exert their function without entering the 
cytoplasm or if they are imported into a quiescent cell and then enter the 
peptidoglycan recycling pathway, we constructed JJ1886 strains deleted for the 
oligopeptide transporter operon, oppABCDF 25-29, and also the peptidoglycan 
tripeptide-specific delivery protein mppA 27,30-32. Both deletion strains grew well in 
liquid glucose minimal medium and became quiescent when plated at 103 CFU per 
plate, similar to parent strain JJ1886; furthermore, like JJ886, both strains were 
stimulated to proliferate by addition of stem peptides to the plate (Fig. S8B and S8D), 
indicating that it is not necessary for the stem peptides to enter the cytoplasm via the 
Opp transporter in order to act as a signal to overcome quiescence.  
 
Discussion 
Here, we show that two virulent UPEC strains, CFT073 and JJ1886, enter a quiescent 
state when plated on glucose minimal agar, and this state is prevented and reversed by 
proliferants, including peptidoglycan stem peptides consisting of four (e.g., E. coli) or 
five (e.g., S. aureus) amino acids. Quiescence is a unique physiological state described 
for E. coli that is common among UPEC strains (i.e., 51/145 isolates tested) and is 
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quorum-regulated. The quiescent state is adopted by an entire population of cells 
under a given growth condition, in contrast to a persister state, which occurs in a small 
percentage of cells within a population 33-37. Adoption of a quiescent, non-
proliferative state would require many physiological systems to slow (e.g., 
transcription, translation) or stop (e.g., DNA replication, division and peptidoglycan 
synthesis). Accordingly, we observed that quiescent cells adopt a filamentous 
morphology, failing to successfully divide or proliferate despite extended incubation 
(Fig. S1B). Finally, different strains respond to known proliferants with varying 
sensitivities, suggesting that either the sensitivity of detection or the regulatory control 
over physiological pathways varies among strains. For example, L-lysine is sufficient 
to induce proliferation of quiescent JJ1886 cells (Fig. 4B), whereas L-lysine must be 
supplemented with either L-methionine or L-tyrosine to induce proliferation of 
quiescent CFT073 cells 6.  While lysine import is one way to overcome quiescence, 
stimulation by peptidoglycan stem peptides occurs independently of the lysine 
importer lysP, suggesting that there are multiple regulatory inputs that enable 
reinitiation of the cell cycle. It is also possible that detection of peptidoglycan 
fragments stimulates lysine biosynthesis or increases intracellular lysine concentration 
in a coordinated manner, which then induces proliferation. 
 
Muropeptide fragments are known to resuscitate dormant Mycobacterium smegmatis 
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38 and to signal B. subtilis endospores to germinate 11. Here we showed that in E. 
coli, PG stem tetra- and pentapeptide fragments not only cause cells to reenter the cell 
cycle, but may also act as a signal to communicate the presence of a quorum, 
independent from uptake by the Opp import system. Previously, it was shown that an 
oppA mutant is far less infective in a mouse UTI model than the wildtype 39, and it 
was suggested that small oligopeptides, present in high concentration in urine 39, are 
imported and serve as major nutrients for CFT073 growth in urine 39. Here, neither 
the pentapeptide nor the tetrapeptide entered the quiescent cells via Opp, suggesting 
that they are imported by a second, presently unknown, oligopeptide permease, or act 
as signals in the periplasm and are recognized by a membrane receptor or signal 
transduction system that, when activated, promotes cell proliferation. The 
serine/threonine kinase PknB is a widely conserved PG binding protein that is 
important for germination of spores in B. subtilis 11; however, no similar proteins 
have been found thus far in E. coli.  
 
The cause(s) of recurrent UTIs are complex 40; however, it appears that UPEC can 
bind to, enter, and replicate within superficial facet cells in the mouse and human 
bladder epithelium, resulting in intracellular biofilm-like communities (IBCs) 40,41. 
IBCs escape from infected superficial facet cells within hours of development and 
several cycles of IBC formation occur, but each successive round is associated with a 
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reduced replication rate and smaller IBCs 15. The infected superficial facet cells 
exfoliate, exposing underlying transitional epithelial cells that become infected with 
IBC-derived UPEC progeny. Upon infection of transitional cells, small numbers of 
UPEC appear to enter a latent or quiescent intracellular state in endosomal vesicles (2 
to 12 cells/vesicle), establishing QIRs 42 that are resistant to antibiotic treatment and 
are a possible cause of recurrent UPEC infection.  If the physiology of UPEC 
quiescence in vitro is similar to that in vivo, understanding how PG stem peptides 
prevent in vitro quiescence at the molecular level may help inform how to prevent 
recurrent UPEC infections in humans. 
  
Methods 
 
Bacterial strains, plasmids and growth conditions. E. coli strains and plasmids used 
in this study are listed in Table 1. Clinical UPEC isolates were obtained from the 
collections of J. Johnson (29 strains) and E. Sokurenko (5 strains) (Table 2). Lennox 
broth (LB) supplemented with agar (LB agar) was used for routine cultivation. Liquid 
glucose (0.2% or 0.4%, where indicated) M9 minimal medium and 0.2% glucose M9 
minimal agar plates were prepared as described previously 6. Gene deletions were 
constructed by λ-Red recombination as described in Datsenko and Wanner and 
  
 
44
confirmed by sequencing 43. Culture density was monitored by growing cells in liquid 
0.2% glucose M9 minimal medium and measuring OD600 at the indicated times. 
 
Plasmids for complementation of both CFT073 ∆lysP and CFT073 ∆argP gene 
deletions were constructed using expression vector pBAD24. Both genes were 
amplified from CFT073 by whole colony PCR (lysP, 5’ 
atcaagaattcacatgggttccgaaactaaaactacagaag 3’, 5’ 
tagataagcttttatttcttatcgttctgcgggaacttc 3’; argP, 5’ 
atcaagaattcacatgcaacccgacacaaaattgtgtcatag 3’, 5’ 
tagataagcttttaatcctgacgaagaactttgtgaccataatcg 3’). The resulting PCR products were 
digested with EcoRI and HindIII. Digested PCR products were ligated into 
EcoRI/HindIII-digested pBad24. Both pLysP and pArgP plasmid constructs were 
verified by sequencing and then transformed into either CFT073 ∆lysP or CFT073 
∆argP deletion strains by electroporation. To test for complementation, transformants 
were grown overnight in 0.4% glucose M9 minimal medium with ampicillin (50 μg 
ml-1) and were assayed for quiescence on 0.2% glucose minimal agar supplemented 
with arabinose (0.1%), where indicated.  
 
Quiescence assay. Quiescence assays were performed as described previously 6. 
CFT073 and JJ1886 wild type and mutant strains were grown on LB agar plates 
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overnight at 37 °C. An isolated colony was used to inoculate 5 ml of 0.4% glucose M9 
minimal medium, incubated at 37 °C with shaking overnight, and then diluted to 
between 103 to 108 CFU, as indicated, in 3 ml 0.2% glucose M9 minimal medium 
containing 0.75% Difco noble agar held at 45 °C. Inoculated soft agar was 
immediately poured onto plates containing a 12 ml layer of 0.2% glucose M9 minimal 
medium with 1.5% noble agar or directly into an 8.5 cm2 polystyrene culture dish.  
Putative proliferants, including actively growing cells, amino acids, Dap (2,6- 
diaminopimelic acid), sterile human urine and peptidoglycan fragments, were added 
and plates were incubated at 37 °C for 24 to 72 h, where indicated, and then imaged.  
 
Microscopy. Overnight cultures of CFT073 were grown to stationary phase in 0.4% 
glucose M9 minimal medium. Five µl of a 3-log diluted culture was spotted onto LB 
agar or 0.2% glucose M9 minimal medium with 1.5% noble agar and, where indicated, 
supplemented with L-lysine (1 mM) and L-methionine (1 mM), then allowed to dry 
for 1 h at room temperature. Plates were incubated at 37 °C for 24 or 48 h. Cells were 
harvested onto a glass cover slip, resuspended in phosphate-buffered saline (PBS) with 
ethylenediaminetetraacetic acid (EDTA) (1 mM) and applied to an agar gel pad 
containing 0.2% glucose M9 minimal medium with 0.5% noble agar. Cells were 
visualized by differential interference contrast (DIC) microscopy using a Zeiss LSM 
700, and images were captured on an AxioCam HRc high-resolution camera with ZEN 
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2012 software. Images were processed using Adobe Photoshop CC and analyzed using 
NIH ImageJ software.  
 
Peptidoglycan fragment separation. E. coli CFT073 was inoculated in 10 ml of M9 
minimal medium containing 0.4% glucose and incubated at 37 °C shaking (200 rpm) 
for 24 h. Cultures were subsequently inoculated into one liter of M9 minimal medium 
containing 0.4% glucose and incubated for 24 h shaking (175 rpm). Methods used for 
PG isolation were adapted from Desmarais et al., 2014 44. Cells were harvested at 
5,000 x g for 10 min at room temperature and pellets were resuspended in 3 ml of M9 
minimal medium. Cell suspensions were transferred into 6 ml of 6% sodium dodecyl 
sulfate (SDS) and boiled for 3 h with stirring. After 3 h, heat was discontinued, and 
cell suspensions were stirred overnight at room temperature. Cell suspensions were 
centrifuged at 262,000 x g for 30 min, pellets were resuspended in liquid 
chromatography mass spectrometry (LCMS) grade water and further centrifugation 
and wash steps occurred until no SDS remained. The final pellet was resuspended in 
900 μl of 10 mM Tris-HCl with 0.06% w/v NaCl and 100 g of Pronase E was added 
to the cell suspension and then incubated for 2 h at 60 °C. After incubation, 200 μl of 
6% SDS was added and the mixture was boiled at 100 °C for 30 min. Samples were 
centrifuged at 262,000 x g for 30 min and washed 4 times with LCMS grade water. 
The final pellet was resuspended in 200 μl of PBS and incubated with 200 U of 
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mutanolysin (Sigma-Aldrich) at 37 °C overnight. Samples were centrifuged at 16,000 
x g for 10 min to remove cellular debris, PG supernatant was collected for further 
testing. Mutanolysin was removed by ultrafiltration using a polyethersulfone filter 
with a 3-kDa molecular weight cut-off. 
 
Analytical high-performance liquid chromatography (HPLC) was used to purify the 
PG extract. HPLC experiments were performed on a Shimadzu prominence-I LC-
2030C equipped with a PDA detector model LC-2030/2040, pump LC-2030, and 
autosampler LC-2030. Preparative HPLC experiments were completed with a Waters 
XBridge Analytical C18 5 μm, 4.6 × 250 mm column at 30 °C using a solvent gradient 
of 10-100% B (5 mM ammonium acetate with 15% acetonitrile pH 4.89) run over 16 
min against solvent A (5 mM ammonium acetate pH 4.37). Solvent B was held at 10% 
for 4 min prior to the gradient and 100% B was held for a subsequent 4 min at the 
conclusion of the method. Individual peaks were collected according to 205 nm 
absorbance values at 205 nm. Initial chemical characterization was carried out by 
liquid chromatography mass spectrometry (LCMS) on a Thermo Fisher ISQ EC 
coupled to a Shimadzu Prominence-i LC-2030 system. Chemical separation utilized 
the same mobile phase gradient as previously with a reduced flow rate of 0.6 ml min-1. 
Chemical characterization of pure compounds was undertaken using electrospray 
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ionization mass spectrometry (ESIMS) using an AB Sciex TripleTOF 4600 
spectrometer and LCMS/MS experiments. 
 
Methods of LCMS/MS were performed on a AB Sciex TripleTOF 5600 spectrometer 
coupled to a Waters H class UPLC. Methods of LC mirrored that of initial screening 
with an adjusted flow rate of 0.5 ml min-1 on an XBridge Analytical C18 5 μm, 4.6 × 
250 mm column. Acquisition (SWATH) was performed in positive ionization mode. 
The method specific parameters were as follows: gas 1 (GS1) 55 psi, gas 2 (GS2) 60 
psi, curtain gas (CUR) 25 psi. The source-specific parameters were: temperature 
(TEM) 500 °C, ion spray voltage floating (ISVF) 5500 V, declustering potential (DP): 
100, collision energy (CE) 10 and collision energy spread (CES) 15. An initial time-
of-flight (TOF) scan was collected from m/z 100 to 1500 and SWATH data was 
acquired (m/z 200-1100) over 36 SWATH windows per cycles with a window size of 
m/z 25 and a m/z 1 overlap between windows.  
 
Peptidoglycan from B. subtilis (Sigma-Aldrich) or S. aureus (Sigma-Aldrich) (10 mg 
ml-1) was incubated with 200 U of mutanolysin at 37 °C overnight. Peptidoglycan-
derived stem peptide fragments including ‘A-E-K-A-A’ pentapeptide (L-Ala-D-Glu-
L-Lys-D-Ala-D-Ala (Sigma-Aldrich), ‘K-A-A’ tripeptide (acetyl-L-Lys-D-Ala-D-Ala) 
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(Sigma-Aldrich) and ‘A-E-Dap’ tripeptide (L-Ala-D-Glu-mDap) (AnaSpec), were 
each tested at 5 μl (2 mM) against strains JJ1886, JJ1886 ∆oppABCDF and JJ1886 
∆mppA (103) after growth on M9 minimal agar with 0.2% glucose for 24 h at 37 °C. 
 
Amidase cleavage of disaccharide tetrapeptide. The amiD gene sequence coding for 
residues 18 through 276 was amplified from E. coli MG1655, cloned into pET-24b 
using NdeI/HindIII restriction sites to incorporate a C-terminal hexahistidine tag (5’ 
actgacatatggcaggcgaaaaaggcat 3’, 5’ gcagtaagcttatcctgcccgtatttc 3’) and expressed in 
BL21 (λde3). This resulted in removal of the N-terminal signal sequence and lipid 
modification site. The cells were grown in LB supplemented with 50 μg ml-1 
kanamycin at 37 °C to an OD600 of 0.8. Expression was induced with isopropyl-β-D-
thiogalactoside (1 mM) for 3 h at 30 °C. Cells were harvested by centrifugation at 
6,000 x g for 30 min at 4 °C and resuspended in 25 ml of 25 mM Tris-HCl (pH 7.8) 
buffer containing 150 mM NaCl, 1 mM MgCl2 and 10% glycerol. Cells were lysed by 
French press. Soluble cell extracts were collected by centrifugation at 30,000 x g for 
30 min at 4 °C, then applied to TALON Superflow resin (GE Healthcare), washed 
with 10 column volumes of lysis buffer and eluted with an imidazole gradient. Buffer 
was exchanged by PD-10 desalting column to remove imidazole. Isolated E. coli PG 
disaccharide tetrapeptide was digested with 315 ng of AmiD in 8.5 mM Tris-HCl (pH 
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7.8), 50 mM NaCl, 0.3 mM MgCl2 and 3% glycerol for 26 h at 37 °C. Cleavage was 
confirmed by LCMS analysis as described above. 
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TABLE 1.  Prevalence of quiescence among UPEC ST131 isolates  
 
a Strains were seeded at 103 CFU and 105 CFU on 0.2% glucose M9 minimal agar 
plates and incubated at 37 °C for 24 h, (+) represents quiescent, (-) represents non-
quiescent. 
b Denotes strains that are quiescent when seeded at both 103 CFU and 105 CFU on 
0.2% glucose M9 minimal agar and grown at 37 °C for 24 h. 
     
Strain  
 
Sequence type ST131 
Clade 
Quiescent at 103 CFU 
and reversed by  
Lys and Met a 
Source, 
reference 
CFT073 ST73 n/a + b 6 
Nissle 1917 ST73 n/a + b 6 
JJ1886 ST131 H30Rx/ C2 + c J. Johnson 
JJ1887 ST131 H30Rx/ C2 - J. Johnson 
JJ2547 ST131 H30Rx/ C2 + c J. Johnson 
JJ2050 ST131  - J. Johnson 
JJ2528 ST131 H30R1/ C1 - J. Johnson 
MVAST0036 ST131 H30R1/ C1 - J. Johnson 
MVAST014 ST131 H30R1/ C1 + c J. Johnson 
H17 ST131 H22/ B0 - J. Johnson 
JJ1901 ST131  - J. Johnson 
JJ2087 ST131 H22/ B - J. Johnson 
JJ1999 ST131 H22/ B - J. Johnson 
MVAST167 ST131 H41/ A - J. Johnson 
MVAST020 ST131 H41/ A - J. Johnson 
JJ2134 ST131 H30Rx/ C2 + b J. Johnson 
JJ2183 ST131 H30Rx/ C2 - J. Johnson 
JJ2489 ST131 H30Rx/ C2 - J. Johnson 
QUC02 ST131  - J. Johnson 
JJ2118 ST131 H30R1/ C1 - J. Johnson 
JJ2193 ST131 H30R1/ C1 - J. Johnson 
JJ2210 ST131 H30R1/ C1 - J. Johnson 
JJ2578 ST131 H30R1/ C1 - J. Johnson 
JJ2608 ST131 H30R1/ C1 - J. Johnson 
MVAST038 ST131 H30R1/ C1 - J. Johnson 
MVAST046 ST131 H30R1/ C1 + J. Johnson 
MVAST077 ST131 H30R1/ C1 - J. Johnson 
MVAST084 ST131 H30R1/ C1 - J. Johnson 
MVAST131 ST131 H30R1/ C1 - J. Johnson 
MVAST158 ST131 H30R1/ C1 - J. Johnson 
MVAST179 ST131 H30R1/ C1 + b J. Johnson 
JJ2546 ST131  - E. Sokurenko 
JJ2548 ST131  + b E. Sokurenko 
JJ2963 ST131  - E. Sokurenko 
JJ2974 ST131  + b E. Sokurenko 
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c Denotes strains that are quiescent when seeded at 103 CFU, but non-quiescent when 
seeded at 105 CFU on 0.2% glucose M9 minimal agar plates and grown at 37 °C for 24 
h.   
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Figures 
 
Fig. 1. The quorum-regulated quiescent state of E. coli CFT073 cells on glucose 
M9 minimal agar is reversible. (A) CFT073 cells (104 CFU) were plated onto M9 
minimal agar with 0.2% glucose.  A 5 μl solution of L-lysine (1 mM) and L-
methionine (1 mM), sterile human urine, or an actively growing colony of CFT073 
was transferred to the center of the plate, cells were incubated for 24 h at 37 °C, and 
the zone of growth surrounding the challenge site was monitored. (B, C) Zones of 
growth expand with time after addition of an actively growing colony of CFT073 up 
to 72 h. (D) Removal of the actively growing colony at 24 h has no effect on zonal 
expansion. White arrows indicate position of stimulant addition, brackets indicate the 
zone of colony growth and scale bars are 1 cm in length. 
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Fig. 2. Quiescent CFT073 cells are filamentous at 24 h. (A) CFT073 cells were 
grown on LB agar or 0.2% glucose minimal agar at 37 °C with and without L-lysine 
(1 mM) and L-methionine (1 mM), harvested at 24 h and visualized by DIC 
microscopy. Scale bars are 5 μm in length. (B) Violin plot representing cell length 
distribution at 24 h for 200 cells grown under conditions described in (A). 
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Fig. 3. Quiescent CFT073 ∆lysP and ∆argP cells fail to proliferate with L-lysine. 
All strains, including CFT073, CFT073 ∆lysP, CFT073 ∆argP, were plated on M9 
minimal agar with 0.2% glucose at 104 CFU and then challenged with a 5 μl solution 
of L-lysine (1 mM) and L-methionine (1 mM), sterile human urine or an actively 
growing colony of MG1655 transferred to the center of the plate. CFT073 ∆lysP cells 
containing pLysP or pBad24, where indicated, were supplemented with 50 μg ml-1 
ampicillin and 0.1% arabinose. CFT073 ∆argP cells containing pArgP or pBad24, 
where indicated, were supplemented with 50 μg ml-1 ampicillin. Plates were incubated 
at 37°C for 24 h. 
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Fig. 4. ST131 strain JJ1886 displays quorum dependent growth. (A) JJ1886 cells 
were plated onto 0.2% glucose M9 minimal agar with and LB agar at 105 and 103 
CFU.  JJ1886 displays quorum dependent growth at 103 CFU on glucose M9 minimal 
agar. (B) JJ1886 (103 CFU) were plated onto 0.2% glucose M9 minimal agar.  A 5 μl 
solution of L-lysine (1 mM) and L-methionine (1 mM), L-lysine (1 mM), L-
methionine (1 mM), sterile human urine, or an actively growing colony of CFT073 
was transferred onto a JJ1886-seeded plate and plates were incubated for 24 h at 37 
°C.  
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Fig. 5. Peptidoglycan fragments promote proliferation of quiescent JJ1886 cells. 
High resolution LCMS total ion counts (TIC) including (A) mutanolysin-digested 
crude E. coli PG, which was tested for stimulating proliferation of quiescent JJ1886 
cells plated at 103 CFU on 0.2% glucose M9 minimal agar, inset; (B) elution of a PG 
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tripeptide (L-Ala-D-Glu-mDAP), [M+H]+ 391.632 (m/z), similar to an E. coli 
fragment and corresponding test for quiescence reversal, inset; (C) elution of a PG 
pentapeptide (L-Ala-D-Glu-L-Lys-D-Ala-D-Ala), [M+H]+ 489.380 (m/z), identical to 
a S. aureus PG pentapeptide and corresponding test for quiescence reversal, inset; (D) 
elution of a NAG-NAM disaccharide, [M+K]+ 535.128 (m/z), and corresponding test 
for quiescence reversal, inset; and (E) elution of a disaccharide tetrapeptide, [M+H]+ 
940.573 (m/z), isolated from crude E. coli PG and corresponding test for quiescence 
reversal, inset; (F) products of the enzymatic reaction of E. coli-derived disaccharide 
tetrapeptide isolated from HPLC and then digested with AmiD to produce tetrapeptide 
(L-Ala-D-Glu-mDAP-D-Ala), [M+H]+ 462.198 (m/z), and corresponding test of 
reaction products for quiescence reversal, inset. Candidate proliferants were collected 
and tested in the quiescence assay as described in Methods and plates were incubated 
at 37 °C for up to 24 h. Where shown, white arrows indicate position of proliferant 
addition. Scale bar is 1 cm in length. 
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TABLE S1.  E. coli strains and plasmids used for genetic analyses and 
constructions in this study 
 
E. coli 
Strain or Plasmid 
Genotype Identifier Source, reference  
or construction 
Strains 
  CFT073 Strr 
 
Spontaneous streptomycin-
resistant mutant of CFT073 
 
CFT073 
 
6 
  MG1655   
  BL21 (λde3)    
LAM-rph-1 
F- ompT gal dcm lon hsdSB(rB- 
mB-) λ(de3[lacI lacUV5-T7 gene 
1 ind1 sam7 nin5])  
MG1655 45 
EMD Millipore, 
USA  
 
  ED0052      CFT073 Strr ∆lysP::parE-kan                                  CFT073 
∆lysP 
CFT073; λred 
  ED0070          CFT073 Strr ∆argP::cat                                CFT073 
∆argP 
CFT073; λred 
  JJ1886 
  ED0118 
 
JJ1886 ∆mppA::cat 
JJ1886 
JJ1886 
∆mppA 
46 
JJ1886; λred 
  ED0131 
 
Plasmids 
JJ1886 ∆oppABCDF::cat JJ1886 
∆oppAB
CDF 
JJ1886; λred 
 
  pKD46   
  pKD3 
  pKD267   
  pKD119 
amp 
cat 
kan 
tet 
  43 
43 
B. Wannera 
43 
  pBAD24     
  pLysP 
  pArgP 
  pet-AmiD 
amp (expression vector) 
amp Para::lysP 
amp Para::argP 
kan, (∆N17)amiD-His6 
 
pLysP 
pArgP 
47 
This study 
This study 
This study 
 
a J. Teramoto, K. A. Datsenko, and B. L. Wanner, unpublished  
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Supplementary Figures 
 
Fig. S1. Quiescent CFT073 cells are filamentous at 48 h. (A) CFT073 cells were 
seeded  on 0.2% glucose M9 minimal agar plates and incubated for 24 h at 37 °C at 
low density (104 CFU), which promotes quiescence, and at high density (108 CFU), 
which prevents quiescence and promotes proliferation, leading to a lawn of colony 
growth on the agar plate. (B) CFT073 cells were grown on 0.2% glucose M9 minimal 
agar plates at 37 °C, harvested at 0 and 48 h and visualized by DIC microscopy. Scale 
bars are 5 μm in length. Arrows indicate position of failed septa. (C) Violin plot 
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representing cell length distribution at 0 h (n = 200) and 48 h (n = 72), grown under 
conditions described in (B). 
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Fig. S2. UPEC strain growth in glucose M9 minimal medium. (A) CFT073, 
CFT073 ∆lysP, CFT073 ∆argP and (B) JJ1886 were grown in 0.2% glucose M9 
medium at 37 °C for 24 h with OD600 measured every 2 h from 0 to 12 h and 22 to 24 
h. All strains grow robustly overnight in glucose M9 minimal medium.  
0 6 12 18 24
0.0
0.5
1.0
1.5
2.0
2.5
Time (h)
O
D
6
00
CFT073
CFT073 Δ argP
CFT073 Δ lysP
0 6 12 18 24
0.0
0.5
1.0
1.5
2.0
2.5
Time (h)
O
D
60
0
JJ1886 
A B 
  
 
71
 
Fig. S3. D-lysine and diaminopimelic acid (Dap) fail to stimulate proliferation of 
CFT073 and JJ1886 cells on glucose M9 minimal agar. (A) CFT073 (104 CFU) and 
(B) JJ1886 (103 CFU)  were seeded on 0.2% glucose M9 minimal agar and challenged 
with a solution of either (A) L-lysine (1 mM) and L-methionine (1 mM), D-lysine (1 
mM) and L-methionine (1 mM), Dap (1 mM) and L-methionine (1 mM), (B) L-lysine 
(1mM), D-lysine (1 mM) or Dap (1 mM). Plates were incubated for 24 h at 37 °C and 
imaged. Arrows indicate position of stimulant addition. Scale bars are 1 cm in length. 
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Fig. S4. E. coli, B. subtilis and S. aureus peptidoglycan fragments stimulate 
proliferation of CFT073 and JJ1886 cells. (A, C) CFT073 (104 CFU) and (D) 
JJ1886 (103 CFU) cells were plated onto 0.2% glucose M9 minimal agar plates and 
challenged with a mixture of digested (A) CFT073 PG, (C, D) B. subtilis or S. aureus 
PG or (A) PBS. Plates were incubated (D) 24 h at 37 °C and (A, C) 48 h at 37 °C. (B) 
Digested E. coli PG was titrated (0 to 10 μg) on JJ1886 seeded plates and CFU per 
zone was calculated.  White arrows indicate position of stimulant addition. Scale bars 
are 1 cm in length. 
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Fig. S5. Peptidoglycan fragments, including a S. aureus pentapeptide, stimulate 
proliferation of quiescent UPEC cells. (A) CFT073 (104 CFU), CFT073 ∆lysP and 
(B) JJ1886 (103 CFU) cells were plated onto 0.2% glucose M9 minimal agar and 
challenged with a mixture of digested B. subtilis peptidoglycan (50 μg), S. aureus 
pentapeptide (A-E-K-A-A) (5 μg) or water. Plates were incubated for 48 to 72 h at 37 
°C in (A).  (B) Quiescent JJ1886 cells were challenged with early (4 to 10 min) or late 
(10 to 20 min) fractions of mutanolysin digested E. coli peptidoglycan fractionated by 
HPLC. Plates were incubated for 24 h at 37 °C. Arrows indicate position of proliferant 
addition and scale bars are 1 cm in length. 
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Fig. S6. Candidate proliferants tested for reversal of JJ1886 quiescence. LCMS 
profiles of total ion counts (TIC) for a tripeptide (acetyl-L-Lys-D-Ala-D-Ala), 331.25 
[M+H]+ (m/z) (A), similar to an S. aureus PG fragment, which was tested for 
stimulating proliferation of quiescent JJ1886 cells plated at 103 CFU per plate on 0.2% 
glucose M9 minimal agar, inset; (B) elution of a PG pentapeptide identical to a S. 
aureus fragment and corresponding test for quiescence reversal, inset; (C) Candidate 
proliferants including NAG (0.4 mM), NAM (0.4 mM) and NAG-NAG (1 mM) were 
tested for their ability to stimulate quiescent JJ1886 cells (103  CFU per plate) on 0.2% 
glucose M9 minimal agar plates and plates were incubated for 24 h at 37 °C. White 
arrows indicate position of proliferant addition and scale bars are 1 cm in length. 
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Fig S7. E. coli peptidoglycan fragment analysis by tandem mass spectrometry. 
Tandem mass spectrometry profiles showing total ion counts (TIC) for (A) crude 
peptidoglycan extracted from E. coli and extracted ion counts (XIC) for fragments 
from digested E. coli peptidoglycan and including LCMS/MS fragmentation for (B, E) 
disaccharide tetrapeptide, (C, F) disaccharide tripeptide and (D, G) disaccharide 
dipeptide. 
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Fig. S8. Analysis of quiescence stimulation by PG tetra- and pentapeptides. E. coli 
peptidoglycan tetrapeptide was generated in situ by digestion of disaccharide 
tetrapeptide with purified AmiD. (A) AmiD as purified by IMAC and analyzed by 
SDS-PAGE. (B) AmiD, disaccharide tetrapeptide and AmiD-digested disaccharide 
tetrapeptide, which released NAG-NAM and tetrapeptide, were tested for the ability to 
stimulate proliferation of quiescent JJ1886, JJ1886 ∆oppABCDF and JJ1886 ∆mppA 
cells plated at 103 CFU on M9 minimal agar with 0.2% glucose or (C) quiescent 
CFT073 cells plated at 104 CFU onto M9 minimal agar with 0.2% glucose and 
incubated for 48 h. (D) S. aureus PG stem pentapeptide (L-Ala-D-Glu-L-Lys-D-Ala-
D-Ala) (5 μg) was tested for the ability to stimulate proliferation of quiescent JJ1886, 
JJ1886 ∆oppABCDF and JJ1886 ∆mppA cells plated at 103 CFU on M9 minimal agar 
with 0.2% glucose and incubated for 24 h at 37 °C. Where indicated, brackets 
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highlight areas of stimulated growth and white arrows show position of stimulant 
addition. Scale bar is 1 cm in length. 
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MANUSCRIPT 2: This manuscript has been written for publication in mSystems. The 
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Abstract 
Bacteria produce a wide range of secondary metabolites that influence the health and 
behaviors of neighboring cells.  These chemically mediated interactions are difficult to 
decipher since bacteria are both secreting and reacting to suites of compounds at any 
given time. Visualization of these metabolic exchanges on agar surfaces has been 
aided by Matrix-Assisted Laser Desorption Ionization-Time of Flight Imaging Mass 
Spectrometry (MALDI-TOF IMS).  In this study, we investigated chemical 
interactions between colonies of two marine bacteria, Vibrio parahaemolyticus 
PSU5429 and Bacillus pumilus YP001.  When colonies of the two bacteria were 
grown in close proximity on an agar surface, we observed commencement of 
swarming motility by the V. parahaemolyticus. As the vibrios moved closer to the 
Bacillus, a zone of bacteria lysis appeared around the B. pumilus colony.  MALDI-
TOF IMS suggested that lipopeptides secreted by the Bacillus were responsible for 
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inducing swarming motility. Genomic and chemical investigation of YP001 verified 
the production of lipopeptides and amicoumacin antibiotics, and purified compounds 
recapitulated the induction of swarming and antibiosis, respectively, when tested 
against V. parahaemolyticus. In this scenario, lipopeptide production induces the 
vibrios to swarm towards a lysis zone, resulting in a possible ‘catch and kill’ effect. 
These results demonstrate the complexity of behaviors and outcomes by microbes 
under the simultaneous influence of different allelochemicals and suggest possible 
interplays between antibiotics and compounds that induce motility. 
 
Importance 
Bacterial secondary metabolism provides a wealth of chemically diverse molecules 
possessing wide-ranging biological activities.  Many of these molecules are expected 
to mediate interactions with other organisms, especially other microbes.  However, 
deciphering the possible ecological roles of individual compounds is difficult due to 
small spatial scales and low compound abundance.  In this study, we used a 
combination of MALDI-TOF imaging mass spectrometry, biosynthetic gene cluster 
analysis, and secondary metabolite identification to investigate chemical interactions 
between the marine bacteria Vibrio parahaemolyticus and Bacillus pumilus. Our 
results imply an interplay between lipopeptides produced by B. pumilus that induce 
swarming motility in the vibrio, causing the latter to move toward an antibiotic lysis 
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zone. These observations highlight the complexity of chemical interactions between 
microorganisms when multiple compounds are simultaneously secreted and suggest 
that multiple secondary metabolites could work in concert to influence outcomes. 
 
Introduction 
Microbial communities use chemical communication for synchronizing the 
behaviors of cells, coordinating key processes such as movement, secretion of 
secondary metabolites, bioluminescence, virulence factor production, and the 
formation of biofilms (1). Bacteria also secrete molecules for defensive purposes, iron 
acquisition, and to enhance motility, such as surfactants that modify surfaces to enable 
coordinated movements such as swarming (2). These biosynthetic processes are 
energetically expensive and ineffective strategies for individual cells but become 
advantageous when undertaken collectively in a population.  
Deciphering the intended ecological functions of microbial secondary 
metabolites is challenging due to the small scales on which these interactions occur 
and the complexity of unraveling simultaneous responses to multiple signals.  Recent 
advances in imaging mass spectrometry (IMS) techniques have helped enable the 
visualization of chemically mediated microbial interactions (3).  IMS methods, such as 
Matrix-Assisted Laser Desorption Ionization-Time of Flight Imaging Mass 
Spectrometry (MALDI-TOF IMS), provide a spatial map of ionizable molecules on a 
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surface as they diffuse away from a source such as a microbial colony. Visualizing the 
metabolic exchanges between groups of cells can provide clues to the ecological 
functions of secondary metabolites and aid in the formulation of hypotheses for how 
compounds influence competition outcomes. 
Bacteria belonging to the genus Bacillus are recognized as prolific producers 
of allelochemicals, especially biologically active peptides.  The antibiotics polymyxin 
B and colistin are examples of medically useful peptide drugs derived from Bacillus 
species (4,5).  Surfactins are cyclic lipopeptides that lower surface tension and enable 
coordinated swarming, a form of social motility, observed with many Bacillus species 
(6).  Surfactins have also been implicated in antagonism toward other microbes, 
initiation of biofilm production, surface attachment, and as chemoattractants (7-12). 
MALDI-TOF IMS is particularly well suited to detection and characterization of 
secreted peptides and has proven useful in prior studies of chemically-mediated 
microbial interactions between Bacillus and other bacteria (12,13). 
Our interest in bacteria interactions in marine aquaculture settings led us to 
investigate the chemical interplay between Bacillus pumilus YP001 and V. 
parahaemolyticus PSU5429, a prevalent marine pathogen in aquaculture. When co-
cultured on an agar surface, the vibrio colony was observed to commence swarming 
motility in the direction of the Bacillus colony.  As the vibrios approached the Bacillus 
colony, a lysis zone became visible, suggesting that both chemoattraction and 
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antibiosis were acting upon the motile vibrio cells.  To better understand how 
metabolic exchanges drive this microbial interaction, we combined MALDI-TOF 
IMS, genome analysis, and studies of purified compounds. Here we demonstrate how 
multiple compounds may act in concert to combine chemoattractant and antibiosis 
effects on a community of V. parahaemolyticus. 
 
Results 
B. pumilus YP001 induces V. parahaemolyticus to swarm toward a lysis zone. B. 
pumilus YP001 was isolated from an egg bearing female American lobster Homarus 
americanus in Narragansett Bay, RI. As part of a binary screening effort to identify 
marine bacteria displaying antibiosis toward Vibrio parahaemolyticus, we observed 
that YP001 colonies created zones of inhibition when grown on a lawn of V. 
parahaemolyticus PSU5429, suggesting the production of a compound(s) with growth 
inhibitory properties (Figure 1b). To explore this interaction further, we next spotted 
colonies of YP001 and PSU5429 in close proximity on YP30 agar plates.  
Surprisingly, after incubation at 27 °C for 24 hours, the V. parahaemolyticus was 
observed to commence swarming motility in the direction of the Bacillus colony 
(Figure 2).  However, at a distance of approximately 8 mm, the motile PSU5429 
appeared to be impeded from closer approach to the YP001, further consistent with the 
production of an antibiotic compound. 
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MALDI-TOF IMS reveals metabolic exchanges between bacteria colonies and 
suggests the role of lipopeptides in swarming by V. parahaemolyticus.  We 
hypothesized that bacterial secondary metabolites were responsible for the induction 
of swarming motility by the vibrio and the lysis zone around the B. pumilus colony. A 
MALDI-TOF IMS approach was implemented to visualize the presence of secondary 
metabolites secreted by the two bacteria colonies as they interacted on a thin agar 
plates. Bacillus are known to be versatile producers of bioactive peptides (14,15) and 
MALDI-TOF is well suited for the detection of such molecules.  This approach has 
been previously applied to IMS investigations of secondary metabolism by Bacillus 
growing on agar surfaces (12). 
 Colonies of YP001 and PSU5429 were cultured in close proximities (1, 8 and 
13 mm) on thin agar (10 mL) YP30 plates in triplicate for 24, 48, and 96 h. Swarming 
motility by PSU5429 and antibiosis were observed in these experiments after 24 hours 
and continued up to 96 hours.  Plates from each time point were prepared for MALDI-
TOF IMS by fixing the thin agar onto a steel MALDI plate with matrix (50:50 α-
cyano-hydroxycinnamic acid and dihydroxybenzoic acid) and drying under 
desiccation.  
MALDI-TOF-IMS conducted in the positive ion mode revealed a 2-D spatial 
map of chemical interactions between the two bacteria colonies (Figure 3).  Prominent 
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features included the secretion of compounds with m/z 1058 [M+Na]+ and 1072 
[M+Na]+  surrounding the B. pumilus colony and extending to the area where V. 
parahaemolyticus was swarming (Figure 3).  The predicted size of these compounds 
suggested that they could be lipopeptides.  For example, the Bacillus secondary 
metabolites surfactin C-15 and D (Figure S1 and S2) have molecular weights of 
1035.68 and 1049.70, respectively, and therefore could account for the IMS observed 
features.  IMS showed that these molecules diffused all the way to the vibrio colony, 
consistent with influencing of the observed swarming motility. Consistent with this 
theory, surfactants are reported to modify surfaces to promote swarming motility of 
bacteria such as observed for B. subtilis, Pseudomonas spp., Proteus mirabilis, V. 
parahaemolyticus, and Serratia spp. (16-20). Additional signals with m/z 1050, 1058, 
1059, 1072, 1073, 1086 and 1087 were also observed to diffuse away from the 
Bacillus colony, and might indicate production of the related lipopeptides pumilacidin 
A-C, and E-G respectively (Figure 3 and S3) (21). Compounds corresponding to these 
ions were observed to diffuse across the agar surface in a manner similar to the 
surfactins, further suggesting the production of pumilicidins as possible contributors to 
the induction of swarming motility in the vibrios.   
Other IMS features included ions localized within the zone of inhibition, 
suggesting a possible role in the observed antibiosis  (Figure 3).  Prominent ions 
included those with m/z 445, 467, 672, 823, and 899.  Based on a review of antibiotic 
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compounds produced by Bacillus species, the ions at m/z 445  and 467 were consistent 
with the expected [M+H]+ and [M+Na]+, respectively, of the molecule amicoumacin 
B, an antibacterial compound produced by a hybrid PKS-NRPS biosynthetic pathway 
in Bacillus sp. (22). 
 
Genome analysis of B. pumilus YP001 supports the production of lipopeptides 
and amicoumacin antibiotics.  IMS suggested roles of different compounds for 
induction of swarming motility and antibiosis.  Whole genome sequencing was 
performed to investigate the biosynthetic potential of B. pumilus YP001 and possibly 
identify secondary metabolites consistent with the IMS results. A draft genome from 
YP001 was assembled and comprised 14 contigs, averaging 3,640,419 bp in size, with 
an average GC content of 53.5%. The genome was annotated with the Rapid 
Annotation Subsystem Technology (RAST) server, which identified 3,797 open 
reading frames (23). The genome was next analyzed by antiSMASH (Antibiotics and 
Secondary Metabolite Analysis Shell) (24) to identify biosynthetic gene clusters 
(BSGs) involved in secondary metabolite production. Overall, 12% of the genome (i.e. 
427,1038 nt) was broadly characterized as being involved in secondary metabolite 
biosynthesis. The genome of B. pumilus YP001 encoded eleven major secondary 
metabolism BGCs, including three non-ribosomal peptide synthase (NRPS) clusters, 
two terpene biosynthesis pathways, type 1 polyketide synthase genes and one hybrid 
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NRPS cluster. Alignments to previously published biosynthetic pathways were carried 
out in Geneious (Figure S4).   
Analysis of a NRPS cluster indicated that YP001 was capable of surfactin 
production.  This biosynthetic gene cluster showed 53.4% pairwise identity to the 
surfactin producing proteins srfAA-D from Bacillus amyloliquefaciens BGC0000443 
(Geneious Global alignment, 70% similarity cost matrix). Individual gene alignments 
were carried out using NCBI-nBLAST, revealing strong similarities to the surfactin 
synthase subunits srfAA (100%), srfAB (82%), srfAC (66%), and srfAD (64%) (Table 
1). 
The hybrid NRPS pathway was found to possess high pairwise identity 
(64.1%) for the biosynthetic gene cluster (BGC) in Bacillus subtilis subsp. 
inaquosorum KCTC 13429 that produces amicoumacin antibiotics (Geneious Global 
alignment, 70% similarity cost matrix). Alignments of biosynthetic genes AmiA-M 
from the KCTC 13429 strain showed high homology between these two biosynthetic 
gene clusters (Table 2) (25). Amino acid binding site analysis was carried out using 
Geneious to predict monomer substrate binding in adenylation and ketosynthase 
domains (Table S1 and S2), further establishing a potential biosynthesis pathway for 
amicoumacin production. 
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Isolation and structure identification of lipopeptides, lipoamides and 
amicoumacins produced by B. pumilus YP001.  The results from the MALDI-TOF-
IMS experiments and genome analysis encouraged the isolation and structure 
characterization of bioactive compounds produced by B. pumilus YP001 in order to 
validate their identities and bioactivities.  B. pumilus YP001was cultured in 9 x 1L of 
artificial seawater supplemented with yeast (1 g/L) and peptone (5 g/L) in the presence 
of XAD-16 resin (Figure S5). XAD resin adsorbs secondary metabolites secreted into 
the media during bacteria growth and has been shown to increase the recovery of 
secondary metabolites (26). After seven days, the resin was recovered by filtration, 
extracted with organic solvents, and the resulting crude extract was partitioned 
between ethyl acetate and water.  The organic soluble compounds were fractionated by 
C18 reversed-phase column chromatography and HPLC and guided by bioassays 
against V. parahaemolyticus PSU5429. The bioassays indicated that separate 
compounds were responsible for induction of swarming motility and antibiotic 
activity. Specifically, the PSU5429 swarming motility was induced by fractions that 
appeared enriched for lipopeptides by 1H NMR spectroscopy. In contrast, the 
antibiotic activity, observed as zones of growth inhibition in disc diffusion assays, 
tracked with fractions containing a compound with a m/z of 447 [M+Na]+.   
 Four compounds (1-4) were isolated from the culture extracts that promoted 
swarming motility by PSU5429. Lipoamide B2 (1) was obtained as an optically active 
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colorless oil {[α] 21.8

  -7.0 (c 0.1, MeOH)}. High-resolution electrospray ionization 
mass spectrometry (HRESIMS) analysis established the molecular formula of 1 as 
C17H32N2O4 (m/z 351.2226 [M+Na]+, calcd. 351.2254), requiring three degrees of 
unsaturation. The IR spectrum of 1 displayed characteristic absorptions indicative of 
amide bond (νmax 1663 cm-1) (Figure 4). Its 13C NMR and DEPT spectra (Table S3), 
combined with HSQC data, disclosed 17 carbon resonances, including two methyls, 
ten sp3 methylenes, two sp3 methines, and three sp2 quaternary carbons (three carbonyl 
carbons at δC 173.0, 172.3 and 171.9, two of which were assigned as amide carbonyl 
carbons based on the MS and IR spectrum of 1. The above functional groups 
accounted for all three degrees of unsaturation, implying a linear structure in 1. 
The existence of an asparagine unit (unit A, Figure 5) was determined by the 
clear 1H-COSY correlations of H-1’ (δH 7.94, d, J=7.5 Hz)/H-2’ (δH 4.45 m)/H2-3’ (δH 
2.42, m; δH 2.56, m) and key HMBC correlations from these protons to C-6’ (δC 
173.0) and C-4’ (δC 171.9), along with the identical HMBC correlations from H-1’ to 
C-2’ (δC 48.9) and from H2-5’ (δH 6.85, s; δH 7.37, s) to C-4’. Two methyl signals at δH 
0.83 (d, J= 6.6 Hz) and δH 0.80 (t, J= 7.5 Hz) and the broad signal at δH 1.23 strongly 
indicated the presence of anteiso-methyl-branched fatty acid chain which was then 
verified by the detailed analysis of COSY correlations of H3-12/H-10 (δH 1.32, m) and 
H2-11 (δH 1.11, m; δH 1.32, m), H3-13/H2-9 (δH 1.07, m; δH 1.27, m) and H-10, as well 
as the HMBC correlations from H3-12/H3-13 to C-10 and H-10 to C-9. Furthermore, 
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the HMBC correlation of H2-2 (δH 2.07, t, J= 7.2 Hz) and C-1 (δC 172.3), bearing in 
mind the MS of 1, determined the presence of a 12-membered side chain with a C-1 
acyl group and a methyl branch at the antepenultimate carbon (unit B, Figure 5). 
Finally, the connection between two units (units A and B) was established by the 
correlations from H-1’/H-2’/H2-2 to C-1, allowing the planar structure construction of 
1. The NMR spectroscopic data of 2 indicated that its structure was closely related to 1 
and represents a structural isomer of the previously published lipoamide C (27).  
Parent masses are insufficient to differentiate lipopeptides produced by 
Bacillus sp. therefore the identities of compounds 3 and 4 were determined by 
extensive investigations of spectroscopic data. Pumilacidin and surfactin differ by one 
amino acid residue at the fourth position, corresponding to leucine and valine, 
respectively. Compound 3 was isolated from B. pumilus YP001 broth monoculture as 
a white powder; [α] 21.8

 -2.22 (c 0.2, MeOH). Prominent features in the 1H NMR 
spectrum were consistent with lipopeptide structures, and 1H-1H COSY correlations, 
identified spin systems corresponding to glutamic acid, leucine, and valine amino 
acids (Figures S17, S19). The presence of leucine points strongly towards isolated 
compounds 3 and 4 belonging to the family of surfactins known to be produced by 
Bacillus pumilus. HRESIMS data confirmed the molecular formula of compound 3 to 
be C53H93N7O13 (m/z 1034.6790 [M-H]-, calcd 1034.6753) corresponding with the 
known surfactin C-15 (Figure S1).  
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Compound 4 was isolated as a white powder; [α] 21.8

 -4.07 (c 0.2, MeOH) from 
broth monoculture and the molecular formula of compound 4 was established as 
C54H95N7O13 based on HRESIMS (m/z 1048.7000 [M-H]-, calcd. 1048.6910) (Figure 
S2). Based on this data in combination with one- and two dimensional NMR data, 
compound 4 was identified as surfactin D. Comparison of the optical rotations of 3 
and 4 against published values were consistent with these assignments of surfactin C-
15 and D (28). Taken in combination with BGC analysis, this evidence was confirmed 
the structures of compounds 3 and 4. 
Amicoumacin B was obtained as a yellow oil. Based on HRESIMS (m/z 
447.1648 [M+Na]+) data we established a molecular formula as C20H32N2NaO4. The 
1H NMR spectra exhibited three aromatic proton singlets for a tri-substituted aromatic 
unit at δH 6.81, 7.47, and 6.84 (H-5, H-6, and H-7), three oxymethines at δH 4.69, 3.95, 
and 3.72 (H-3, H-8’ and H-9’), two nitrogen-bonded methines δH 4.20 and 3.31 (H-5’ 
and H-10’), and two methyl resonances at δH  0.85 and 0.89 (H-1’ and H-2’) consistent 
with a isocoumarin ring structure (Table S4), and matching the published values for 
amicoumacin B (insert ref containing published NMR data for amicoumacin B). 
MALDI-TOF IMS was used to visualize the isolated amicoumacin B as it diffused 
through agar from a 10 mM spot on a thin agar MALDI plate (Figure S6). 
Amicoumacin B ionized readily by MALDI-TOF IMS, further confirming its identity 
in the co-colony IMS experiments. 
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V. parahaemolyticus swarms toward a source of highly purified surfactins or 
lipoamides.  A swarming motility assay was used to investigate the effects of specific 
compounds on initiation of swarming by V. parahaemolyticus PSU5429. Close 
proximity of PSU5429 to either B. pumilus YP001 or discs loaded with lipopeptide 
compounds 1-4 stimulated swarming behavior (Figure 6). Isolated surfactins and 
lipoamides stimulated swarming motility in PSU5439 with variable effects. Surfactins 
C-15 and D induced strong directional swarming when loaded onto discs at 10 and 
100 µg/disc (Figure 6). In comparison, lipoamides 1 and 2 caused weak swarming 
response at 200 µg (Figure S6).   No swarming was observed in response to discs 
loaded with amicoumacin B (data not shown). 
The motility bioassays were repeated against three other marine Vibrio sp. to 
test if YP001 compounds could stimulate swarming motility in other species. 
Swarming motility was induced by surfactin C-15 and D for in the oyster pathogen V. 
coralliilyticus RE22, but not for V. harveyi BB120 or V. anguillarum NB10Sm. 
Neither V. parahaemolyticus PSU5429 nor V. coralliilyticus RE22 were observed to 
swarm in control experiments conducted in the absence of compounds from B. 
pumilus YP001 (Figure S8).  All four Vibrio sp. were susceptible to the antibiotic 
effects of amicoumacin B (Figure 1b-d). 
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Discussion 
The IMS results showed that the Vibrio parahaemolyticus colony was 
subjected to a barrage of secondary metabolites secreted by B. pumilus YP001, five of 
which were identified using a combination of genome analysis and compound 
isolation. Four molecules were found to promote swarming motility in V. 
parahaemolyticus, namely surfactins C-15 and D and lipoamides B2 and C. In 
addition, the isocoumarin antibiotic amicoumacin B demonstrated killing effects and 
likely contributes to an observed zone of growth inhibition surrounding the Bacillus 
colony.  
MALDI-TOF IMS also revealed ions belonging to compounds that were not 
isolated from broth cultures of YP001, and these might further contribute to the 
microbial interactions. For example, ions observed by IMS suggest the production of 
pumilacidins A, B, C, E, and G by B. pumilus YP001 (Figure 3 and S3). Other 
molecules corresponding to ions concentrated in the antibiotic zone were not identified 
as known Bacillus compounds or isolated from liquid monocultures of YP001. Taken 
together, this shows that the vibrio cells experience a complex chemical environment 
when in proximity to B. pumilus that influences both their phenotypes and survival. 
One interpretation of these combined effects on the vibrio colony is that the 
Bacillus colony promotes swarming motility toward a zone of growth inhibition, 
resulting in lysis of nearby vibrio cells and providing additional nutrients to support 
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colony growth. The closely related bacterium Bacillus subtilis has previously been 
shown to engage in bacteria cannibalism, whereby a subpopulation secretes peptide 
toxins to lyse sibling cells in order to harvest their nutrients (29).  Bacillus subtilis 
produces the proteins Slf and bacteriocin-like toxins which lyse nearby cells in a form 
of bacterial cannabalism (30,31).  The dual secretion of motility promoters and 
antibiotics might serve a similar purpose in interspecies interactions.  It was recently 
shown that the bacterium Paenibacillus dendritiformis swarms toward a source of 
surfactins, consistent with these molecules serving as interspecies recruitment factors 
(12).  The results here extend this possibility to more distantly related bacteria species, 
since both V. parahaemolyticus and V. coralliilyticus commenced swarming motility 
in response to the Bacillus lipopeptides.  In contrast, the surfactins displayed no 
growth alterations against V. harveyi and V. anguillarum NB10 (Figure S8), although 
these bacteria do not possess the laf gene cluster most often conserved for the 
production of lateral swarming flagellar (32,33). 
An alternative hypothesis is that the V. parahaemolyticus benefits by coopting 
surfactin production to enable its swarming motility. This could enable more rapid 
colonization of the surrounding environment.  Motility can increase antibiotic 
resistance, up regulate virulence factor production and increase the speed of infection 
on solid or semi solid surfaces such as tissues (34,35). While some bacteria species are 
sensitive to the antimicrobial effects of lipopeptides, including clinically relevant 
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Gram-positive and Gram-negative strain (36), others are clearly resistant and might 
therefore capitalize on their surface modifying properties.  In this instance, the 
Bacillus might be producing antibiotics to fend off the approaching swarm of vibrios.   
Motility in V. parahaemolyticus differs from other swarming bacteria because 
it possesses two distinct flagellar systems. A single polar flagellum is utilized for 
swimming while peritruchous lateral flagella are utilized during swarming (37). In 
contrast to this study, lipopeptides were previously reported as inhibitors of swarming 
motility in Vibrio alginolyticus (38). Surfactins act to decrease surface tension, 
allowing directional movement of cells. Lipopeptides have also been shown to cause 
ion channel formation in lipid bilayer membranes, creating imbalances in trans-
membrane ion fluxes (20,39,40). This proposed pore formation has been indicated as a 
mechanism of action of surfactins as antimicrobial and antifungal agents (41-44). The 
production of surfactin as a competitive interspecies chemical signaling strategy has 
been shown for Salmonella, Escherichia, Bacillus and Staphylococcus species (45,46), 
and now for Vibrio. Surfactins are also important mediators of intraspecies 
communication and phenotypes, including promoting motility on surfaces, attachment, 
and biofilm production (7-12).  Hence, these molecules serve multiple purposes for 
mediating both intra- and interspecies interactions. 
  Genome sequencing was employed to probe secondary metabolite biosynthetic 
gene clusters and dereplicate IMS signals.  Eleven biosynthetic gene clusters, 
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accounting for 12% of the genome, were identified for YP001, suggesting the 
impressive biosynthetic capabilities of this bacterium. This is comparable to Bacillus 
subtilis which dedicates ~10% of its genome to secondary metabolism (36). Previous 
bioinformatic investigation of Bacillus sp. found that strains contain 1 to 16 BGCs of 
which some are highly conserved (NRPS, bacteriocin, and terpene) across all strains 
whereas other BGCs (PKS, lanthipeptide and thiopeptide) are highly variable (47). 
Combining genome mining with highly sensitive IMS techniques provided evidence 
for the compounds involved in the observed microbial interactions, but chemical 
isolations further verified several of the molecules. The bioassay guided approach also 
helped identify lipoamides as inducers of swarming motility in V. parahaemolyticus.  
Isocoumarin antibiotics such as the amicoumacins are commonly produced by 
various species of Bacillus (48) as well as some actinomycetes (49).  The 
amicoumacins inhibit protein synthesis (50,51) and possess antibacterial properties 
against clinically relevant Gram-positive bacteria (25). In this study we demonstrate 
that the antibacterial activity of amicoumacin B against V. parahaemolyticus (Figure 
7). Although purified amicoumacin B readily ionized on agar by MALDI-TOF IMS 
and produced a ZOI against V. parahaemolyticus, production of amicoumacin B from 
B. pumilus colonies was initially somewhat challenging to measure by IMS. 
Differences could indicate that antimicrobial activities are predominantly cell-bound 
or that the presence of the extracellular polysaccharide (EPS) matrix and other surface 
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structures hinder the ionization of these molecules (13). Other high intensity ions were 
present in the lysis zone surrounding the B. pumilus colony which were not identified, 
suggesting that other anti-vibrio compounds might also contribute to the observed 
antibiosis.  
 Bacillus and Vibrio species are ubiquitous in most marine environments and 
are likely competitors for resources such as nutrients and space.  The results from this 
study suggest that these relationships are mediated by complex chemical interactions 
where multiple secondary metabolites may work in concert to achieve advantageous 
outcomes.  Understanding the roles of specific molecules and their combinations could 
help inform new ways to influence bacteria behaviors in aquaculture systems and treat 
infections.  
 
Materials and Methods 
General experimental procedures: NMR experiments were conducted using an 
Agilent Inova NMR 500 MHz spectrometer in DMSO-d6 (99.99%, Sigma-Aldrich, St. 
Louis, MO, USA) at 25 °C (referenced to residual DMSO at δH 2.54 and δC 39.5). 
High Resolution Electrospray Ionization mass spectra (HR-ESI-MS) and tandem mass 
spectra were acquired using a TripleTOF 4600 spectrometer (AB Sciex) operating in 
negative ion mode. Flash chromatography was completed using an Agilent 971-FP 
flash purification system (Agilent Technologies, Santa Clara, CA, USA) with Biotage 
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SNAP KP-C18-HS 120g cartridges (Biotage, Charlotte, NC, USA). HPLC 
experiments were performed on a Shimadzu Prominence-I LC-2030C equipped with a 
PDA detector model LC-2030/2040, pump LC-2030, and autosampler LC-2030.  
Optical rotations were acquired on a Jasco P-2000 polarimeter and UV was taken on 
Beckman Coulter DU 800. IR experiments were carried out on Thermo Nicolet 380 
FT-IR. MALDI-TOF IMS was carried out on a Bruker Autoflex Speed instrument. 
 
Isolation, sequencing and computational genome analysis of Bacillus pumilus 
YP001. Strain YP001 was isolated from the egg mass of a female American lobster, 
Homarus americanus, collected in Narragansett Bay (12/16/15; Fort Weatherall, 
Jamestown, RI, USA). The eggs were gently brushed with a sterile cotton swab, which 
was then stored in a sterile whirl-pak sampling bag for transportation to the lab. The 
cotton tip was transferred into 1.5 mL of sterile artificial seawater (Instant Ocean ™; 
Spectrum Brands) under aseptic conditions and then vortexed.  A 100 µL aliquot was 
plated on artificial seawater agar plates supplemented with yeast (1 g/L) and peptone 
(5 g/L) (YP30). YP001 was picked from the plate as a single colony, streaked to purity 
(twice on YP30 plates) and cryogenically stored at -80 °C in glycerol stocks. 
Total DNA was extracted from overnight cultures of B. pumilus YP001 grown 
in liquid YP30 using the Promega Wizard genomic DNA purification kit (Promega, 
USA). The DNA was resuspended in 2 mM Tris-HCL buffer (Bio Basic). DNA was 
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quantified using a NanoDrop 1000 spectrophotometer (ND-1000) and checked for 
quality on a 1% agarose gel stained with ethidium bromide. The resulting DNA was 
sequenced on an Illumina MiSeq sequencer at the Genomics and Sequencing Center at 
the University of Rhode Island. Total genomic DNA was sheared by sonication 
(Covaris S220), and paired end libraries were prepared using the SMARTer PrepX 
DNA Library Kit on a SMARTer Apollo system (Takara Bio, USA). Reads were 
trimmed using the CLC Genomic Workbench (version 9.5.3, Qiagen, Hilden, 
Germany) for quality, ambiguous base pairs, adaptors, duplicates and size with default 
parameters. A draft genome was assembled using the SPAdes assembler (Algorithmic 
Biology Lab, St. Petersburg Academic University of the Russian Academy of 
Sciences). Coverage was determined by mapping reads to a draft genome of Bacillus 
pumilus (CP016784.1). The genome was annotated using the Rapid Annotation 
Subsystem Technology (RAST) server and analyzed by antiSMASH (Antibiotics and 
Secondary Metabolite Analysis Shell) for secondary metabolite biosynthesis gene 
clusters. The draft genome assembly has been deposited in DDBJ/EMBL/GenBank 
under accession number PRJNA434728. Sequence alignments for amicoumacin 
biosynthetic cassettes were analyzed for identity through Geneious and NCBI-delta-
blastp.  
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Isolation and Structure Elucidation of YP001 secondary metabolites. B. pumilus 
YP001 was grown in 9 x 1 L of YP30 broth for 7 days at 25 °C and 150 rpm on a New 
Brunswick C10 rotary shaker table in the presence of Amberlite XAD-16 resin (10 
g/L; Sigma Aldrich). Following cultivation, the resin was collected by filtering 
through two layers of cheesecloth, washed three times with DI water (4 L total) to 
remove salts, and then extracted with 500 mL of 1:1 CH2Cl2 and CH3OH, followed by 
1 L of CH3OH, and finally 200 mL EtOAc.  The combined solvents were removed by 
rotary evaporation and the resulting extract was partitioned between 100 mL H2O and 
three washes of 500 mL ethyl acetate. The combined organic layers were concentrated 
in vacuo to yield 0.8 g of extract.  
The organic fraction was separated by flash chromatography using a 
Combiflash Rf200 equipped with a 50 g C18 RediSepRf High Performance Gold 
column (Teledyne ISCO). A linear solvent gradient of 5-100% CH3OH in H2O (0.1% 
formic acid) was run over 20 min at a flow rate of 40 mL/min, then the mobile phase 
was held at 100% CH3OH for 5 min. Individual peaks were collected by monitoring 
UV absorbance at 254 nm, yielding 6 fractions (QW1-144-1 to QW1-144-6). HPLC 
separations were completed with a Waters XBridge preparative C18 5 μm, 10 × 250 
mm column at 4 mL/min a linear solvent gradient of 5-100% B (MeOH) run over 16 
minutes against solvent A (water + 0.1% formic acid). Solvent B was held at 5% for 4 
min prior to starting the gradient and 100% B was held for a subsequent 4 min 
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following the gradient. Pure lipoamide B2, and C and were isolated by preparative 
HPLC following the same solvent gradient yielding 11.8 mg and 11.9 mg respectively. 
Analytical HPLC experiments were carried out on a Waters XBridge Analytical C18 5 
μm, 4.6 × 250 mm column at 1 mL/min using the same mobile phase methods. 
Purification of surfactin C15 and D followed a solvent gradient of 80-100% B 
(MeOH) run over 16 min against solvent A (water + 0.1% formic acid). Solvent B was 
held at 80% for 4 min prior to gradient beginning and 100% B was held for a 
subsequent 4 min. Amicoumacin B was isolated to purity through flash 
chromatography collection. In total, amicoumacin B, Surfactin C15, and surfactin D in 
yields of 11.6 mg, 2.6 mg, and 6.3 mg, respectively. 
 
Antimicrobial Activity Assays. B. pumilus YP001 was tested for antimicrobial 
activity against the pathogens Vibrio anguillarum NB10Sm, Vibrio harveyi BB120, 
Vibrio coralliilyticus RE22 and Vibrio parahaemolyticus PSU5429 through a 
modified diffusion assay (52). V. parahaemolyticus PSU5429 was grown for 24 h in 
YP30, diluted 10-3 fold, and 100 μL of the diluted culture was spread on 15 mL YP30 
agar. A 5 μL spot of B. pumilus YP001, grown overnight in 10 mL YP30, was added 
in triplicate and incubated at 25 °C. Zones of inhibition were imaged with a BioRad 
gel doc universal hood after 24-48 h at 25 °C.  
 
  
 
104
Swarming Motility Assay. YP001 colonies, extracts and purified compounds were 
tested for induction of swarming motility by V. parahaemolyticus PSU5429. Sterile 
discs were loaded with 20 or 100 μg of test compounds and placed onto the surface of 
a YP30 agar plate. Alternatively, a 5 μL spot of YP001 grown for 24 h in 5 mL of 
YP001 broth was spotted onto a 15 mL YP30 agar plate.  PSU5429 was grown for 24 
h in YP30 broth, diluted to 1x105 CFU/mL in sterile media, and spotted at a distance 
of 3, 8 or 13mm from the disc or colony. Plates were incubated for 24 h at 27 °C and 
then imaged with a BioRad gel doc universal hood. This assay is qualitative for the 
induction of swarming motility.  
 
MALDI-TOF IMS Imaging. MADLI-TOF IMS experiments were carried out on 10 
mL YP30 plates. Strains were plated in triplicate and incubated for up to 96 h. One 
assay from each time point (24, 48 and 96 h) was wet mounted onto a steel MALDI-
TOF plate, coated with 50:50 α-cyano-hydroxycinnamic acid (CHCA) and 
dihydroxybenzoic acid (DHB) matrix and dried in a desiccator for 4 h at 37 °C and 
analyzed by MALDI-TOF IMS. Samples were analyzed by MALDI-TOF IMS at 65% 
laser power, 8.6X gain 500 μm raster in positive ion reflectron mode on a Bruker 
Autoflex Speed instrument.  Data was normalized using total ion count (TIC) or root 
mean square (RMS) as indicated.  
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Figures 
 
Figure 1: Growth inhibition of B. pumilus YP001 against (a) V. harveyi BB120 (b) V. 
parahaemolyticus PSU5429, (c) V. anguillarium NB10Sm, and (d) V. coralliitlyticus 
RE22 after 24 h incubation on YP30 at 27 ºC. 
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Figure 2: Swarming motility assay for B. pumilus YP001 plated in co-culture with V. 
parahaemolyticus PSU5429 at concentrations of (a) 1x105 CFU/mL, (b) 1x102 
CFU/mL, (c) 1x101 CFU/mL, and (d) no dilution. Plate was imaged after 24 h 
incubation at 27 ºC. 
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Figure 3: MALDI-IMS imaging shows the spatial distribution of compounds produced 
during the chemical interaction of B. pumilus YP001 and V. parahaemolyticus 
PSU5429. 
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Table 1: Genes encoding the surfactin biosynthetic gene cluster in B. pumilus YP001, 
their proposed functions and homology to the biosynthetic genes of B. 
amyloliquefaciens BGC0000443. Alignments were carried out in NCBI-nBLAST. 
 
  
Protein 
  
Size (bp) 
  
Predicted Function 
B. pumilus YP001 
Identity (%)     E value 
srfAA 10,755 NRPS 100% 0.0 
srfAB 10,762 NRPS 82.0% 1e-07 
srfAC 3,837 NRPS 65.7% 7e-69 
srfAD 732 Thioesterase 64.3% 9e-13 
ycxD 1,311 Aminotransferase 100% 0.14 
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Table 2: Genes encoding the amicoumacin biosynthetic gene cluster in B. pumilus 
YP001, their proposed functions and homology to the biosynthetic genes of B. subtilis 
subsp. inaquosorum KCTC 13429. Alignments were carried out in NCBI-nBLAST. 
  
Protein 
  
Size (bp) 
  
Predicted Function 
B. subtilis YP001 
Identity (%)          E value 
AmiA 4,497 NRPS 65.1% 6e-84 
AmiB 1,506 Peptidase 66.3% 2e-21 
AmiD 702 Thioesterase 70.6% 5e-54 
AmiE 345 Dehydrogenase 74.4% 9e-62 
AmiF 213 Acyl carrier protein 78.9% 2e-23 
Ami-1 9,096 NRPS-PKS 65.6% 0.0 
Ami-2 2,670 NRPS 64.1% 1e-49 
AmiJ 4,527 PKS 69.8% 0.0 
AmiK 7,554 NRPS-PKS 71.9% 0.0 
AmiL-M 6,429 NRPS-PKS 66.7% 0.0 
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Figure 4: Chemical structure of compounds 1 and 2. 
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Figure 5: 1H−1H COSY and key HMBC correlations for compound 1. 
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Figure 6: Swarming bioactivity of compound 3 at 10 µg (a), 100 µg (b) and compound 
4 at 10 µg (c), and 100 µg (d) after 24 h incubation at 27 ºC on YP30 agar. 
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Figure 7: Effects of purified surfactin (20 µg/disk) and amicoumacin (20 µg/disk) (a), 
surfactin (20 µg/disk) only (b), amicoumacin (100 µg/disk) only (c) and B. pumilus 
YP001 colony (5 µL at 1x105 CFU/mL from a broth culture) (d) on V. 
parahaemolyticus PSU5429 after 24 h incubation at 27 ºC. 
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Supplementary Figures 
 
Figure S1: High resolution TOF-MS for 3 m/z 1034.6790 [M-H]- in negative ion 
mode. The declustering potential was set to -185 and collision energy to -33. 
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Figure S2: High resolution TOF-MS for 4 m/z 1048.7 [M-H]-  in negative ion mode. 
The declustering potential was set to -200 and collision energy to -50. 
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Figure S3: MADLI-TOF IMS total ion counts (TIC) taken after 48 h incubation 
indicating the production of pumilacidin B (m/z 1,059 [M+Na]+), F/G (m/z 1,073 
[M+Na]+), and E (m/z 1087 [M+Na]+).  
  
100%
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Figure S4: Biosynthesis of amicoumacin by B. pumilus YP001 domain predictions 
carried out in Geneious. 
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Table S1: Amino acid sequence alignment for amicoumacin production from B. 
pumilus YP001. 
Protein Size 
(aa) 
Proposed function Identity 
(%) 
Accession No. Proposed Protein 
Alignment 
2163 1413 Aminotransferase, class 
III [B. pumilus] 
99 DW21908.1 Orf1 
2144 4416 Non-ribosomal peptide 
synthetase [B. pumilus] 
100 WP_080984813.1 AmiA 
2143 1542 β-lactamase containing 
hypothetical protein [B. 
pumilus] 
100 WP_050945729.1 AmiB 
2142 981 Peptidase containing 
hypothetical protein [B. 
pumilus] 
100 WP_050945730.1 AmiC 
2141 711 Thioesterase [B. 
pumilus] 
100 WP_050945731.1 AmiD 
2140 858 3-hydroxybutyryl-CoA 
dehydrogenase [B. 
pumilus] 
100 WP_003214220.1 AmiE 
2139 1056 Hypothetical protein [B. 
pumilus] 
100 WP_050945732.1 AmiF 
2138 270 Acyl carrier protein [B. 
pumilus] 
100 WP_050945733.1 AmiG 
2137 1143 Acyl-CoA 
dehydrogenase  [B. 
pumilus] 
100 WP_050945734.1 AmiH 
2136 9090 Hybrid NRPS/T1PKS 
[B. pumilus] 
100 WP_050945735.1 AmiI 
2135 2670 Non-ribosomal peptide 
synthetase [B. pumilus] 
100 WP_050945736.1 AmiJ 
2134 4506 Polyketide synthase B. 
pumilus] 
100 WP_050945737.1 AmiK 
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2133 7233 Polyketide synthase B. 
pumilus] 
100 MY19195.1 AmiL 
2132 6411 Polyketide synthase B. 
pumilus] 
100 WP_050945739.1 
  
AmiM 
2130 1407 Alkaline Phosphatase 
[B. pumilus] 
100 WP_080984808.1 AmiN 
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Table S2: Amino acid sequence alignment for surfactin production from B. pumilus 
YP001. 
Protein Size 
(aa) 
Proposed function Identity/ 
Similarity 
(%) 
Accession No. 
3473 1239 Hypothetical Protein [B. pumilus] 100 WP_050943243.1 
3472 1299 Arsenical efflux pump membrane protein 
ArsB [B. pumilus] 
100 WP_050943242.1 
3471 678 Amino acid transporter permease [B. 
pumilus] 
100 WP_003214368.1 
3470 873 Amino acid ABC transporter substrate 
binding protein [B. pumilus] 
100 WP_050943239.1 
3469 333 DUF2680 domain-containing protein [B. 
pumilus] 
100 WP_050943461.1 
3468 765 MBL fold metallo-hydrolase [B. pumilus] 100 WP_050943237.1 
3467 417 DNA-entry nuclease [B. pumilus] 100 WP_003214307.1 
3466 807 AAC(3) family N-acetyltransferase [B. 
pumilus] 
100 WP_050943235.1 
3465 387 DNA-entry nuclease [B. pumilus] 100 WP_050943233.1 
3464 1698 Methy;-accepting chemotaxis protein [B. 
pumilus] 
100 WP_050943231.1 
3463 429 DNA-entry nuclease [B. pumilus] 100 WP_003214307.1 
3462 2070 Hydantoin utilization protein A [B. 
pumilus] 
100 WP_050943229.1 
3461 1986 Hydantoin utilization protein B [B. 
pumilus] 
100 WP_050943227.1 
3460 1086 ABC transporter ATP-binding protein [B. 
pumilus] 
100 WP_050943226.1 
3459 1092 Polyamine ABC transporter ATP-binding 
protein [B. pumilus] 
100 WP_050943225.1 
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3458 870 ABC transporter protein permease [B. 
pumilus] 
100 WP_003214329.1 
3457 804 ABC transporter protein permease [B. 
pumilus] 
100 WP_003214190.1 
3456 10719 Non-ribosomal peptide synthetase [B. 
pumilus] 
92 WP_003214217.1 
3455 3834 Non-ribosomal peptide synthetase [B. 
pumilus] 
100 WP_050945478.1 
3454 10136 Non-ribosomal peptide synthetase [B. 
pumilus] 
100 WP_050945479.1 
3453 8196 Non-ribosomal peptide synthetase [B. 
pumilus] 
100 WP_050945480.1 
3452 741 Thioesterase [B. pumilus] 100 WP_050945481.1 
3451 912 EamA family transporter [B. pumilus] 100 WP_050945482.1 
3450 1338 PLP-dependant aminotransferase family 
protein [B. pumilus] 
100 WP_050945483.1 
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Figure S5: Chemical isolation scheme from B. pumilus YP001. 
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Table S3: 1H and 13C NMR data (δ in ppm, J in Hz) for compound 1 in DMSO-d6. 
Position Type δC δH (J in Hz) 
1 qC 172.3 − 
2 CH2 35.1 2.07 t (7.2) 
3 CH2 25.2 1.45 m 
4 CH2 28.5 1.23 m 
5 CH2 28.9 1.23 m 
6 CH2 28.9 1.23 m 
7 CH2 28.9 1.22 m 
8 CH2 26.5 1.27 m 
9 CH2 36.0 1.07 m, 1.27 m 
10 CH 33.8 1.32 m 
11 CH2 29.4 1.11 m, 1.32 m 
12 CH3 11.7 0.80 t (7.5) 
13 CH3 19.1 0.83 d (6.6) 
1’ NH − 7.94 d (7.5) 
2’ CH 48.9 4.45 m 
3’ CH2 37.0 2.42 m, 2.56 m 
4' qC 171.9 − 
5’ NH2 − 6.85 s, 7.37 s 
6’ qC 173.0 − 
Recorded at 300 MHz for 1H NMR in DMSO-d6, chemical shifts (ppm) referred to DMSO (δH 2.50). Recorded at 125 MHz for 13C NMR 
in DMSO-d6, chemical shifts (ppm) referred to DMSO (δC 39.5). Assignments were deduced by analysis of 1D and 2D NMR spectra. 
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Figure S6: Swarming assay for (a) lipoamide C (100 µg), and (b) lipoamide B2 (100 
µg) against V. parahaemolyticus PSU5429 after 24 h incubation at 27 ºC. 
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Figure S7: MADLI-TOF IMS ionization of amicoumacin B m/z 425 [M+H]+ and 447 
[M+Na]+ plated at 10 mM in methanol onto a YP30 plate. 
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Figure S8: Swarming assay for 100 µg of surfactin D (i) and C-15 (ii) against (a) 
Vibrio coralliilyticus RE22, (b) Vibrio harveyi BB120, (c) Vibrio anguillarum 
NB10Sm after 48 h incubation at 27 ºC.
6 mm
a a
b b
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Figure S9: 1H-NMR spectrum (500 MHz, DMSO-d6) of compound 1 from B. pumilus 
YP001.  
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Figure S10: 13C-NMR spectrum (500 MHz, DMSO-d6) of compound 1 from B. 
pumilus YP001.  
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Figure S11: 1H−1H COSY NMR spectrum (500 MHz, DMSO-d6) of compound 1 from 
B. pumilus YP001.  
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Figure S12: HSQC NMR spectrum (500 MHz, DMSO-d6) of compound 1 from B. 
pumilus YP001.  
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Figure S13: HMBC NMR spectrum (500 MHz, DMSO-d6) of compound 1 from B. 
pumilus YP001.  
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Figure S14: IR spectrum of compound 1. 
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Figure S15: HRESIMS of compound 1 measured in positive ion mode (m/z 351.2226 
[M+H]+ and 373.2048 [M+Na]+). 
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Figure S16: Lipoamide C (2) IR data. 
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Figure S17: HRESIMS of lipoamide C (2) recorded in positive ion mode (m/z 345.1713 
[M+H]+). 
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Figure S18: 1H-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001.  
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Figure S19: 13C-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001.  
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Figure S20: gCOSY-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001.  
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Figure S21: TOCSY-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001.  
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Figure S22: HSQC-NMR spectrum (500 MHz, DMSO-d6) of surfactin D (4) from B. 
pumilus YP001.  
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Figure S23: 1H-NMR spectrum (500 MHz, DMSO-d6) of surfactin C15 (3) from B. 
pumilus YP001.  
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Table S4. NMR Data for Amicoumacin B (500 MHz) in DMSO-d6. 
Position Type δ C δ H 
1 CO 169.47 - 
2 O - - 
3 CH 81.45 4.69 
4 CH2 29.47 2.85, 3.05 
5 CH 118.94 6.81 
6 CH 136.71 7.47 
7 CH 115.67 6.84 
8 C 161.32 - 
9 C 108.79 - 
10 C 141.15 - 
1’ CH3 21.99 0.85 
2’ CH3 23.79 0.89 
3’ CH 24.44 1.65 
4’ CH2 39.49 1.33, 1.67 
5’ CH 48.54 4.20 
6’ NH - 7.90 
7’ CO 173.08 - 
8’ CH 72.04 3.95 
9’ CH 72.24 3.72 
10’ CH 50.58 3.31 
11’ CH2 33.85 2.18, 2.33 
12’ CO 174.18 - 
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Table S5. NMR Data for AI-77-F (500 MHz) in DMSO-d6. 
Position Type δ H 
1 CO - 
2 O - 
3 CH 4.69 
4 CH2 2.97 
5 CH 6.84 
6 CH 7.49 
7 CH 6.87 
8 C - 
9 C - 
10 C - 
1’ CH3 0.85 
2’ CH3 0.91 
3’ CH 1.65 
4’ CH2 1.23, 1.68 
5’ CH 4.20 
6’ NH 7.70 
7’ CO - 
8’ CH  
9’ CH  
10’ CH  
11’ CH  
12’ CO - 
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Figure S24: 1H-NMR spectrum (500 MHz, DMSO-d6) of AI-77-F from B. pumilus 
YP001.  
 
 
 
 
 
 
155
CHAPTER 4 
 
MANUSCRIPT 3: This manuscript was published in 2018 in the American Society for 
Microbiology Genome Announcements 6 (17) e00313-18. The formatting follows the 
guidelines set forth by the journal. 
 
MANUSCRIPT 4: This manuscript was published in 2019 in the American Society for 
Microbiology, Microbial Resource Announcements 8:e01431. The formatting follows 
the guidelines set forth by the journal. 
 
MANUSCRIPT 5: This manuscript was published in 2018 in the American Society for 
Microbiology Genome Announcements 6 e00314-18. The formatting follows the 
guidelines set forth by the journal. 
 
 
  
 
 
 
 
156
Draft Genome Sequence of the Putative Marine Pathogen Aquimarina sp. I32.4 
 
Hilary J. Ranson, a Jason LaPorte, b Edward Spinard, b Andrei Y. Chistoserdov,c Marta 
Gomez-Chiarri,d David R. Nelson, b David C. Rowley a# 
 
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, 
Kingston, Rhode Island, USAa;  
Department of Cell and Molecular Biology, University of Rhode Island, Kingston, 
USAb;   
Department of Biology, University of Lousiana at Lafayette, Lafayette, Louisiana, 
USA;c  
Department of Fisheries, Animal and Veterinary Sciences, University of Rhode Island, 
Kingston, Rhode Island, USAd; 
 
Running Head: Draft Genome of Aquimarina sp. I32.4 
 
#Address correspondence to David Rowley, drowley@uri.edu.  
 
Author contributions 
H.J.R. designed and performed the experiments. J.L. aided in genomic DNA isolation 
methods. H.J.R. and E.S. carried out the sequence assembly. A.Y.C provided the 
strain. H.J.R. wrote the manuscript. M.G.C., D.R.N. and D.C.R. supervised the study 
and managed the projects. 
 
 
 
 
157
Aquimarina sp. I32.4 (formerly Aquimarina sp. ‘homaria’) is a putative pathogen 
involved in epizootic shell disease in the American lobster Homarus americanus. We 
report here the draft genome sequence for Aquimarina sp. I32.4 and describe virulence 
factors that may provide insight into its mechanism of pathogenicity. 
 
Epizootic shell disease (ESD) is a prevalent and uncontrolled disease affecting 
the carapace of the American lobster Homarus americanus. ESD is characterized by 
formation of lesions on the carapace that exhibit bacterial counts 2-4 orders of 
magnitude higher than the surrounding area (1). The cause of ESD is still debated 
within the scientific literature, but recent studies have suggested the presence of 
Aquimarina sp. ‘homaria’ results in the exacerbation of lesions (2,3,4). Aquimarina 
sp. I32.4 is a Gram negative, chitin degrading bacterium (5). To better understand the 
mechanism of pathogenicity we announce the draft genome sequence of Aquimarina 
sp. I32.4 and describe some potential virulence factors. 
 
 Aquimarina sp. I32.4 was grown in artificial seawater (Instant Ocean) 
supplemented with yeast extract (1 g/L) and peptone (5 g/L) at 25 oC on an elliptical 
shaker (New Brunswick) for 48 hours. Genomic DNA was isolated using Promega 
Wizard DNA purification kit (Promega, USA) and DNA was resuspended in 2 mM 
Tris-HCL buffer (Bio Basic). DNA was quantified using a NanoDrop 1000 
spectrophotometer (ND-1000) and checked for quality on a 1% agarose gel stained 
with ethidium bromide. DNA was sequenced on an Illumina MiSeq sequencer at the 
Genomics and Sequencing Center at the University of Rhode Island. Reads were 
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trimmed using the CLC Genomic Workbench (version 8.5.1) for quality, ambiguous 
base pairs, adaptors, duplicates and size resulting in 1,329,308 paired-end reads.  The 
draft genome was assembled using the de novo assembly algorithm of SPAdes 
assembler (version 3.1.1). Contigs with coverage of >22 reads were processed using 
the CLC Microbial Genome Finishing module with Aquimarina macrocephali JAMB 
N27 (GCA_000520995.1) used as a reference genome. The completed draft genome is 
composed of 244 contigs, averaging 20,446 bp in size (total genome = 4,988,869 bp), 
with an average G+C content of 32.4%. The draft genome was annotated using the 
Rapid Annotation Subsystem Technology (RAST) server and resulted in 4,469 open 
reading frames (6). The closest neighbor identified by SEED viewer 2.0 (7) was 
Gramella forsetii KT0803 (score = 541). 
 
The annotated draft genome of Aquimarina sp. I32.4 encodes for type III and 
IV secretion systems. It has previously been reported that Aquimarina sp. can degrade 
the carapace of H. americanus (1). Accordingly, sixteen putative chitinase genes were 
found, along with three hemolysins and three metalloproteases. Three iron acquisition 
systems were annotated: TonB, including the full compliment of proteins responsible 
for the formation of the TonB-ExbB-ExbD complex, hemin and ferric siderophores 
were identified and could contribute to virulence associated with this strain. The 
RAST annotated draft genome was submitted to antiSMASH (Antibiotics and 
Secondary Metabolite Analysis Shell) for secondary metabolite biosynthesis gene 
cluster analysis (8). Identification of ten clusters for secondary metabolism including, 
T1PKS-NRPS biosynthesis, NRPS and Trans-ATPKS were categorized by 
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antiSMASH. Trans-ATPKS biosynthesis produces structurally diverse molecules in 
other bacteria, including the cytotoxic and antitumor compounds pederin and 
onnamide (9). Other species in this genus have been shown to have algicidal activity 
against toxic cyanobacterium strains (10).  
 
This Whole Genome Shotgun project has been deposited at 
DDBJ/ENA/GenBank under the accession number PGUB00000000. The version 
described in this paper is version PGUB00000000. 
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ABSTRACT 
Thalassobius sp. 31.1 is a putative pathogen involved in epizootic shell disease in 
the American lobster Homarus americanus. We report here the draft genome 
sequence for Thalassobius sp. 31.1 and provide insight into its metabolism and 
links to environmental pollutant degradation. 
 
Thalassobius sp. 31.1 is a Gram-stain-negative, aerobic, motile, rod-shaped 
bacterial strain. This genus is of the class Alphaproteobacteria, family 
Rhodobacteraceae, and order Rhodobacterales. Thalassobius sp. 31.1 was isolated 
from a lesion on the carapace of the American lobster Homarus americanus (1). 
Lesions are the characteristic symptom of epizootic shell disease (ESD) and 
Thalassobius has been indicated as a putative pathogen in lesion formation. Strains of 
the genus Thalassobius have previously been studied for the inability to utilize 
multiple carbon sources (2). However, Thalassobius has been shown to utilize the 
speculative environmental carcinogen phthalate, a chemical widely used in the 
manufacture of plastics, lubricants and textiles (3). These strains contain genes 
required for poly-beta-hydroxybutyrate (PHB) synthesis and genes relating the 
degradation of phenylacetates, an abundant class of environmental pollutants (4). 
 
 Thalassobius sp. I31.1 was grown in artificial seawater (instant ocean) 
supplemented with yeast (1 g/L) and peptone (5 g/L) at 25 °C on an elliptical shaker 
(New Brunswick) for 48 hours. Genomic DNA was isolated using Promega Wizard 
DNA purification kit (Promega, USA) and DNA was resuspended in 2 mM Tris-HCL 
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buffer (Bio Basic). DNA was quantified using a NanoDrop 1000 spectrophotometer 
(ND-1000) and checked for quality on a 1% agarose gel stained with ethidium 
bromide. The DNA was sequenced on an Illumina MiSeq sequencer at the Genomics 
and Sequencing Center at University of Rhode Island. Reads were trimmed using the 
CLC Genomic Workbench (version 8.5.1) for quality, ambiguous base pairs, adaptors, 
duplicates and size resulting in 2,277,834 paired-end reads.  The draft genome was 
assembled using the de novo assembly algorithm of SPAdes assembler (version 3.1.1). 
Contigs with coverage of >44 reads were processed using the CLC Microbial Genome 
Finishing module. The completed draft genome is composed of 62 contigs, averaging 
57,385 bp in size, with an average G+C content of 55.1%. The draft genome was 
annotated using the Rapid Annotation Subsystem Technology (RAST) server and 
resulted in 3,749 open reading frames (5). The closest neighbor identified by SEED 
viewer 2.0 (6) was Silicibacter pomeroyi DSS-3 (score = 508). 
 
The annotated draft genome of Thalassobius sp. 31.1 encodes for type I and 
II/IV secretion systems. RAST annotation identified a suite of paa genes involved in 
phenylacetate degradation, two alkane monooxygenase genes, phbF, a transcriptional 
regulator involved in PHB synthesis (7) and one toluenesulfonate dehydrogenase. The 
annotated draft genome was submitted to antiSMASH (Antibiotics and Secondary 
Metabolite Analysis Shell) for secondary metabolite biosynthesis gene cluster analysis 
(8). Identification of six clusters for secondary metabolism including, homoserine 
lactone, bacteriocin and lantipeptide-bacteriocin were identified.  
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This Whole-Genome Shotgun project has been deposited in 
DDBJ/EMBL/GenBank under accession number PWAA00000000. The version 
described in this paper is the first version, PWAA01000000. 
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Loktanella maritima YPC211 was isolated from the American lobster Homarus 
americanus. We report here the draft genome sequence for L. maritima YPC211 and 
identify genes of potential importance to it’s role within the microbial community.  
 
Loktanella maritima is a Gram negative aerobic bacterium that was originally 
isolated from shallow marine sediments in the Sea of Japan (1). Loktanella spp. appear 
to be ubiquitously distributed in the oceans and have been isolated from Antarctic to 
sub-tropical environments (6). The genus belongs to the class Alphaproteobacteria, 
family Rhodobacterales, and order Rhodobacteraceae. Trappen et al. (2) originally 
proposed the genus to accommodate three species but it has since been expanded and 
modified to contain 15 species (3, 4, 5). The strain Ha06YPC211 produces a 
beige/yellow pigment and was isolated from an egg mass of an American Lobster 
(Homarus americanus) from Jamestown, RI.  
 
 L. maritima YPC211 was grown in artificial seawater (Instant Ocean) 
supplemented with yeast extract (1 g/L) and peptone (5 g/L) at 25 °C on an elliptical 
shaker (New Brunswick) for 24 hours. Genomic DNA was isolated using Promega 
Wizard DNA purification kit (Promega, USA) and DNA was resuspended in 2 mM 
Tris-HCL buffer (Bio Basic). DNA was quantified using a NanoDrop 1000 
spectrophotometer (ND-1000) and checked for quality on a 1% agarose gel stained 
with ethidium bromide. The DNA was sequenced on an Illumina MiSeq sequencer at 
the Genomics and Sequencing Center at University of Rhode Island. Reads were 
 
 
 
 
171
trimmed using CLC Genomic Workbench (version 8.5.1) for quality, ambiguous base 
pairs, adaptors, duplicates and size resulting in 4,491,164 paired-end reads.  The draft 
genome was assembled using the de novo assembly algorithm of CLC Genomic 
Workbench and SPAdes assembler (version 3.1.1). Contigs with coverage of >76 
reads were processed using the CLC Microbial Genome Finishing module. The 
completed draft genome is composed of 13 contigs averaging 264,067 bp in size and 3 
plasmids of 23,839, 6,277 and 215,371 bp in size (total genome = 3,678,360 bp), with 
an average G+C content of 53.5%. The draft genome was annotated using the Rapid 
Annotation Subsystem Technology (RAST) server and resulted in 3,681 open reading 
frames (7).  
 
The annotated draft genome of L. maritima YPC211 encodes for type I, II, III, 
and IV secretion systems. It has previously been reported that Loktanella spp. can 
survive temperature extremes and have been isolated from Antarctic mats (2). 
Accordingly, five putative cold-shock proteins (including: CspA, CspB and CspC) 
were annotated. Additionally, the genome encodes for four hemolysins, two 
metalloproteases and one extracellular protease. Two iron acquisition systems, TonB 
and Hemin (HmuS), were annotated as well as iron-specific hemin and ABC 
transporters. Ferric siderophore related genes were also identified. The RAST 
annotated draft genome was submitted to antiSMASH (Antibiotics and Secondary 
Metabolite Analysis Shell) for secondary metabolite biosynthesis gene cluster analysis 
(8), leading to the identification of four clusters, including a non-ribosomal peptide 
synthetase, type I polyketide synthase, bacteriocin and homoserine lactone 
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biosynthetic gene clusters. L. maritima YPC211 inhibits the growth of the shrimp 
pathogen Vibrio parahaemolyticus when co-cultivated on an agar surface, as 
determined by a zone of inhibition assay (9). Further investigation of these 
biosynthetic gene clusters may aid in characterization of compounds responsible for 
this antibiosis. 
 
This Whole Genome Shotgun project has been deposited in 
DDBJ/ENA/GenBank under accession number PKFN00000000. The version 
described in this paper is the first version, PKFN01000000. 
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CONCLUDING REMARKS 
 
 
Antibiotics have been our frontline defense against bacterial infections for 
decades. However, the increased emergence of antibiotic resistant infections has led to 
a world health crisis. Continued use of broad spectrum antibiotics has caused an 
increase in untreatable and fatal bacterial infections. In this dissertation I have 
explored the potential use of chemical signals to help mediate pathogenic bacterial 
infections. Understanding these chemical signaling strategies may help facilitate new 
treatment strategies. 
Nature has had billions of years of natural selection to perfect chemical 
communication. Bacteria are particularly interesting as their rate of genetic change is 
so high. We are continually reminded that this has driven systems that have no 
redundancy; nothing is made by accident or without purpose. This dissertation shows 
that even very small molecules such as peptidoglycan fragments, previously thought to 
be innocuous, modulate extremely important communications in bacteria. 
Understanding these natural communication pathways could be extremely important in 
treating complex diseases. Bacteria depend on chemical cues for cell-cell 
communications to facilitate group decision making and thus are key to survival. All 
bacteria are capable of manipulating their chemical environment to survive.  
This dissertation works across human health and marine bacterial biodiversity 
to harness the potential of genetically unique bacteria to produce novel chemical 
scaffolds. Most of the world’s microorganisms have yet to be cultured; many of these 
are likely to be in a quiescent state and could harbor therapeutically useful natural 
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products. Genomic data is extremely powerful in predicating biosynthetic pathways 
from unculturable bacteria, allowing targeting of novel natural products. 
Swarming motility and quiescence are phenomenon observed in disease 
causing bacteria. Targeting these strategies for disease persistence as an alternative or 
in combination with antibiotic treatment could significantly decrease the rate of 
antibiotic consumption.  
We are currently in the “post antibiotic era” and the one size fits all approach 
to medicine is being overtaken by personalized medical treatment. Approaching 
bacterial infections through phenotype modulation and control of signaling pathways 
could allow prevention of disease progression without the threat of developing drug 
resistance. This body of work helps to increase our understanding of how specific 
chemical signaling pathways work and provides knowledge of potential avenues for 
alternative treatment of bacterial infections. 
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Additional Results 
  
 Additional figures include isolation schemes for peptidoglycan from live cell 
culture and support structure assignments for muropeptides based on MS/MS 
fragmentation. Further figures show peptidoglycan recycling within the cell and 
indicate E. coli  knockout mutants that were made to strengthen this manuscript. 
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Figure 1: Peptidoglycan isolation scheme indicating bioassay guided fractionation of 
crude peptidoglycan digestion product from E. coli CFT073. 
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Figure 2: Isolation methods for peptidoglycan from E. coli CTF073 cells to produce 
‘crude’ peptidoglycan preparations used for testing in the quiescence bioassay. 
  
E. coli CFT073 plated on LB and incubated for 24 h at 37 ºC.
Single colony picked and innoculated into 10 mL of M9 broth and 
incubated at 37 ºC shaking 150 rpm for 24 h.
5 mL of broth culture innoculated into 1 L of M9 borth media and 
incubated at 37 ºC at 150 rmp for 24 h.
All cells collected into 4 x 50 mL falcon tubes by multiple rounds 
of centrifugation at 5,000 g for 10 min.
Each pellet was resuspended in 3 mL of M9 media.
6 mL of 6 % SDS was added to each tube while 
being boiled and stirred. This was allowed to 
continue for 3 h.
Centrifuged repeatedly at 262,000 x g unt il all of 
the SDS was removed by washing with LCMS water.
Pellet resuspended in 10 mM Tris-HCL with 0.06% w/v NaCL.
100 μg of Pronase E added and incubated for 2 h at 60 ºC.
200 μL of 6 % SDS was added and pellets were boiled at 
100 ºC for 30 min.
Centrifuged at 262,00 x g for 30 min to remove SDS with 
LCMS water.
Pellet re-suspended in 200 μlL of PBS.
Digested with 200 U of mutanolysin at 37 ºC overnight.
Cenreifuged at 16,000 x g for 10 min.
‘Crude’ peptidoglycan.
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Figure 3: Synthesis, recycling and catabolism pathways for peptidoglycan in the cell. 
Indicating transporters on the cellular membrane involved in uptake and regulation 
into the cell. All mutant knockout (MppA, Opp and AmpG) pathways target different 
sources of peptidoglycan transport.  
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Figure 4: High resolution tandem mass spectrometry for disaccharide tetrapeptide 
(NAG-NAM-Ala-Glu-DAP-Ala) as a potential constituent of crude peptidoglycan 
preparations. Total ion counts (TIC) for crude peptidoglycan (a), extracted ion counts 
(XIC) for disaccharide tetrapeptide (b), and MS/MS fragmentation of disaccharide 
tetrapeptide mass to confirm its structure (c). 
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Figure 5: High resolution tandem mass spectrometry for disaccharide tripeptide 
(NAG-NAM-Ala-Glu-DAP) as a potential constituent of crude peptidoglycan 
preparations. Total ion counts (TIC) for crude peptidoglycan (a), extracted ion counts 
(XIC) for disaccharide tripeptide (b), and MS/MS fragmentation of disaccharide 
tripeptide mass to confirm its structure (c). 
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Figure 6: High resolution tandem mass spectrometry for disaccharide dipeptide (NAG-
NAM-Ala-Glu) as a potential constituent of crude peptidoglycan preparations. Total 
ion counts (TIC) for crude peptidoglycan (a), extracted ion counts (XIC) for 
disaccharide dipeptide (b), and MS/MS fragmentation of disaccharide dipeptide mass 
to confirm its structure (c). 
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Figure 7: High resolution tandem mass spectrometry for pentapeptide (Ala-Glu-DAP-
Ala-Ala) as a potential constituent of crude peptidoglycan preparations. Total ion 
counts (TIC) for crude peptidoglycan (a), extracted ion counts (XIC) for pentapeptide 
(b). Ion abundance was too low to accurately assess the structure by MS/MS. 
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Figure 8: High resolution tandem mass spectrometry for tetrapeptide (Ala-Glu-DAP-
Ala) as a potential constituent of crude peptidoglycan preparations. Total ion counts 
(TIC) for crude peptidoglycan (a), extracted ion counts (XIC) for tetrapeptide (b), and 
MS/MS fragmentation of tetrapeptide mass to confirm its structure (c). 
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Figure 9: High resolution tandem mass spectrometry for tripeptide (Ala-Glu-DAP) as 
a potential constituent of crude peptidoglycan preparations. Total ion counts (TIC) for 
crude peptidoglycan (a), extracted ion counts (XIC) for tripeptide (b). Ion abundance 
was too low to accurately assess the structure by MS/MS. 
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APPENDICES 
 
Appendix B: Manuscript 2 
Isolation, chemical screening and in vivo trials of probiotics isolated from the 
American lobster Homarus americanus in Narragansett Bay to treat epizooitic shell 
disease. 
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Cam Pickard, 16S sequencing was done by Grace Underwood. All adult and PL 
lobster trials were carried out by M.H., B.S., M.H., and K.C. 
 
Additional Results 
 
1.1 Bacterial isolation and culture conditions 
 
 Bacterial isolations were carried out from field collection swabs of live wild 
lobsters in Narragansett Bay (12/10/15; Fort Wetherall, Jamestown, RI, USA). Swabs 
were transported from the field site to the lab in sterile Whirl-Pak sampling bags and 
transferred into 1.5 mL of sterile artificial seawater (Instant Ocean ; Spectrum 
Brands) under aseptic conditions. These stocks were then vortexed and diluted 10- and 
100-fold and stored at 4 ºC. Each sample was plated onto artificial seawater (Instant 
Ocean) agar plates (ASW), ASW supplemented with yeast (1 g/L) and peptone (5 g/L) 
(YP30) and, YP30 with chitin (30 g/L). Single, morphologically unique colonies were 
picked, streaked to purity (twice on YP30) and cryogenically stored at -80 ºC in 10 % 
glycerol. A total of 211 bacterial isolates were collected and cataloged for probiotic 
screening.  
 
1.2 Screening against putative pathogens 
 
All 211 bacterial isolates were assessed for antimicrobial activity against the 
putative pathogens involved in lobster shell disease (LSD) (Aquimarina sp. strain 
I32.4 and Thalassobius sp. strain I31.1) and a common fish pathogen Vibrio 
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anguillarum NB10Sm through a modified diffusion assay. A 24 h culture of the 
pathogen was spread over the surface of the agar plates to form a lawn and 5 µL spots 
from 24 h broth cultures of each isolate were added in triplicate and incubated at 25 
ºC. Zones of inhibition (ZOIs) were measures after 24 and 48 h under optimal growth 
conditions for the indicator strains (Table 1). Inhibitory zones were measures using 
EVOS light microscope (Life Technologies). Tests were performed in triplicate with 
measurements taken from the edge of the test colony to the first viable colony of the 
indicator strain. 
 
1.3 Characterization of pathogenic bacteria 
 
Initial efforts concentrated on optimization of growth conditions for these 
pathogenic bacteria. Thalassobius could be easily and rapidly grown in liquid media, 
however Aquimarina could not. Table 2 summarizes some of the growth condition 
attempted to remove the clumping nature of the strains as it interfered with an accurate 
assessment of cellular growth by both OD600 and CFU/mL counts. Both are important 
for developing bioassays for probiotic testing (work carried out by Jason LaPorte and 
Edward Spinnard). 
A computational approach and whole genome sequence analysis was undertaken 
to gain a better understanding of the chemical diversity of these strains. Although the 
genomes for the wild type strains were not available, closely related species of 
Aquimarina showed the potential for extreme chemical diversity in their biosynthetic 
gene clusters (GCGs) (Table 3). Comparably fewer genomes were available for 
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Thalassobius sp. but many important BCGs were identified (Table 4). The methods 
and results obtained from this analysis are published in manuscripts 2, 3, 4, and 5. 
 
1.4 Characterization of probiotic bacteria 
 
Initial screening resulted in the identification of 26 putative probiotic strains. 
These strains were sequenced according to 16S rRNA PCR. Once potential phylogeny 
was substantiated whole genome sequencing was carried out for phylogenetically and 
chemically unique organisms Bacillus pumilus YP001, Loktanella maritima YPC210 
and YPC211.  
 
1.5 Chemical isolations from probiotic bacteria 
 
 Putative probiotic strains were grown in 1L YP30 broth cultures in the 
presence of XAD16 resin for 1 week, after which the resin was filtered through a 
double layer of cheese cloth and extracted with 50:50 dichloromethane (DCM) and 
methanol (MeOH). These ‘crude’ extracts were subsequently tested in a modified disc 
diffusion assay to assess their antibiotic effects against V. anguillarum (Table 5). 
Neither Loktanella strain was able to produce a ZOI from monoculture extracts. This 
topic is covered more thoroughly in appendix B. 
 
1.6 NO to stimulate chemical diversity 
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 To stimulate the expression of potentially silent BSGs, literature reports have 
suggested the use of oxidative stress to produce novel compounds. Preliminary testing 
indicated that sodium nitroprussate concentrations of 1 µM and 10 µM were sublethal 
where as 100 µM and 1,000 µM were both lethal for probiotic strain. Bacterial strains 
(Thalassobius sp. I31.1, Bacillus pumilus YP001, Pseudoalteromonas sp. YPC21, 
Loktanella maritima YPC210 and, Loktanella maritima YPC211) were streaked from 
freezer stocks onto YP30 agar and incubated for 48 h, after which a single colony was 
inoculated into 5 mL of YP30 broth and further incubated for 48 h at 25 ºC 150 rpm. 
The cultures were assessed for CFU/mL using methods outlined previously. Cultures 
were then spiked with sodium nitroprussate (SNP) at final concentrations of 1 µM and 
10 µM. Cultures were allowed to incubate for a further hour before the addition of 
sterile XAD16 resin and a further 24 h before chemical extraction. Resin was filtered 
through a double layer of cheesecloth and extracted with 100 mL of 50:50 
dichloromethane and methanol. Extracts were assessed for their novel metabolite 
profiles via high performance liquid chromatography (HPLC) when compared to the 
same strain under optimal growth conditions. Initial small-scale extraction cultures 
showed no oxidative stress induced novel secondary metabolite production (Figure 1). 
Chromatographic methods utilized a gradient solvent scheme, maintaining 95 % water 
modified with 0.1 % formic acid and 5 % methanol for 4 minutes. Gradient than ran 
for 20 minutes up to 100 % methanol, where it was held for an additional 4 minutes. 
Experiments were carried out on a Shimadzu prominence-I LC-2030C equipped with a 
PDA detector model LC-2030/2040, pump LC-2030, and autosampler LC-2030. The 
column used was XBridge BEH 5 µm C18, 130 Å, column (4.6 mm X 250 mm).  
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1.7 Preparation of combined Loktanella maritima (strains YPC210 and YPC211) 
probiotics for in vivo trials of adult H. americanus  
 
 Probiotic bacteria were grown in YP30 media for 48 h shaking at 25 °C until a 
dense culture was formed. 500 µL of culture stock was inoculated into 100 mL of 
fresh YP30 media and incubated at 25 °C and 125 rpm for 24 h. Cell density was 
measured by absorbance at 600 nm from 100 µL samples on a 96 well plate reader 
(Molecular Devices, Spectromax M2). Cultures were also plated to count CFU/mL 
and form a growth curve from which to measure the probiotic inoculum (Figure 2) 
 Each adult lobster was contained in individual 10 gallon aquarium tanks with 
an ambient water flow through system and a day/night light cycle at the Graduate 
School of Oceanography. Before treatment each lobster was scrubbed with fresh water 
to control for native biofilms. Ten lobsters were kept as a control and an addition 10 
were treated with a probiotic cocktail consisting of 2x105 CFU/mL L. maritima strains 
YPC210 and YPC211 in a 50:50 ratio. Treatments occurred weekly both the day 
before and the day after feeding. Additionally, 10 lobsters received no treatment. All 
aquaria tanks were cleaned once a week to maintain the health of the adult lobsters. 
All lobsters showed little/moderate shell disease, while probiotic treatment appeared to 
induced both egg bearing and mortality. The trial was discontinued after 12 days due 
to 40% mortality with the probiotic treatment group (Table 6). Haemolymph was sent 
for pathology to see if the probiotics are responsive for the mortality incurred in this 
trial.
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Table 1: Zones of inhibition (mm) from screened lobster isolates (5 µL spot plates) 
against Aquimarina sp. strain I32.4, Thalassobius sp. I31.1 and, Vibrio anguillarum 
NB10Sm. ZOI assessed by EVOS light microscope (Life technologies). [–] Indicates 
that no ZOI was observed blanks indicate that the test has not been done. 
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Table 2: Optimizing growth conditions for Aquimarina ‘homaria’. Symbols 
correspond with + (Low Clumps), ++ (Clumps), +++ (High Clumps) and + (Low 
Growth), ++ (Growth), +++ (High Growth). Data from Edward Spinnard. 
Media/Conditions Growth Clumps 
YP-30 (1µM EDTA) +++ +++ 
YP-30 (5µM EDTA) +++ +++ 
YP-30 (10µM EDTA) +++ +++ 
YP-30 Small Stir Rod + - 
YP-30 Large Stir Rod + - 
Marine Minimal Media (3M) + - 
YP-10 + - 
YP-20 ++ + 
YP-30 (175 RPM) +++ +++ 
YP-30 (300 RPM) +++ + 
YP-30 Static +++ - 
Marine Broth +++ +++ 
LB-10 + - 
LB-20 + - 
LB-30 + - 
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Table 3: Data obtained from NCBI for all known Aquimarina genomes and run 
through antiSMASH cluster analysis database.* Aquimarina pacifica and Aquimarina 
agarilytica possess no know biosynthetic gene clusters (BGCs). 
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Table 4: Data obtained from NCBI for all known Thalassobius sp. genomes and run 
through antiSMASH cluster analysis database.  
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Table 5: Monoculture XAD16 extracts activity against V. anguillarum NB10Sm. 
Bacteria were grown in 1L YP30 shaking cultures for 1 week. Cultures contained 
XAD16 throughout the growth period. Cultures inoculated from 5 mL broth cultures 
with 1 mL of dense cell media. 
Strain Identifier Species Disc Diffusion 
(200 µg) 
Disc Diffusion 
(400 µg) 
Ha031151216YPC23 Alteromonas sp. ✓  ✓  
Ha061151216YP001 Bacillus pumilus YP001 ✓  ✓  
Ha061151216YPC21 Pseudoalteromonas sp. ✓  ✓  
Ha061151216YPC22 Pseudoalteromonas sp. ✓  ✓  
Ha061151216YPC210 Loktanella maritima strain YPC210 ✕ ✕ 
Ha061151216YPC211 Loktanella maritima strain YPC211 ✕ ✕ 
Ha091151216YP019 Shewanella sp. ✓  ✓  
Ha10b1151216YPC21 Cobetia sp. ✓  ✓  
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Figure 1. Overlaid chromatograms for SNP spiking experiment at doses 0, 1 and 10 
µM. (A) B. pumilus YP001, (B) Pseudoalteromonas sp. YPC21, (C) 
Pseudoalteromonas sp. YPC22, (D) L. maritime YPC210 (E) L. maritima YPC210. 
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Figure 2. Growth of putative probiotics by measurement of wavelength (600 nm) as a 
proxy for cell density over time. Standard deviation from triplicates calculated for 
each time point. 
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Table 6: Adult H. americanus trial carried out over 12 days. Data from Kathy Castro, 
Barbara Somers, and Mitch Hatzipetro.  
Strains Tested 
N of 
Lobsters 
Mortality (N) of 
Lobsters 
Number of Egg Bearing 
Lobsters 
Loktanella maritima strains YPC210 and 
YPC211 combined 
10 4 3 
Freshwater Scrub 10 0 2 
Control 10 0 0 
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Table 7: Single strain testing of potential probiotics against PL lobsters assessing 
mortality over 3 days. All putative probiotics were tested at 1x106 cell/mL. Work 
carried out by Melissa Hoffman, Kathy Castro, Barbara Somers, and Mitch Hatzipetro.  
Strains Tested 16S Sequence 
PL Lobsters 
(N) 
Mortality (5 days) 
Trial 
Ha031151216YP014 Pseudoalteromonas sp. 12 0 
Ha061151216YPC22 Pseudoalteromonas sp. 12 3 
Ha061151216YP001 Bacillus sp. 12 1 
Ha061151216YPC210 Loktanella sp. 12 0 
Ha061151216YPC211 Loktanella sp. 12 1 
Ha081151216YPC21 Pseudoalteromonas sp. 12 1 
S4 Phaeobacter inhibens 12 2 
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Table 8. Probiotic treatments of PL lobsters with concomitant challenge with the 
putative pathogen Thalassobius I31.1. Mortality was assessed after 3 days. All 
probiotics were tested at 1x106 cell/mL. Melissa Hoffman, Kathy Castro, Barbara 
Somers, and Mitch Hatzipetro. 
Strains Tested 16S Sequence PL Lobsters (N) Mortality (3 days) 
Ha031151216YP014 Pseudoalteromonas sp. 12 0 
Ha061151216YPC22 Pseudoalteromonas sp. 12 0 
Ha061151216YP001 Bacillus sp. 12 0 
Ha061151216YPC210 Loktanella sp. 12 0 
Ha061151216YPC211 Loktanella sp. 12 0 
Ha081151216YPC21 Pseudoalteromonas sp. 12 0 
S4 Phaeobacter inhibens 12 0 
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APPENDICES 
 
Appendix C: Manuscript 5 
Production of known siderophore agrobactin by the marine bacterium Loktanella 
maritima YPC211 when grown in co-culture with Thalassobius sp. I31.1 a putative 
pathogen involved in lobster shell disease.  
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Additional Results 
 
 Loktanella maritima is a Gram-negative, aerobic bacterium originally isolated 
from shallow marine sediments in the Sea of Japan (1). The genus is of the class 
Alphaproteobacteria, family Rhodobacterales, order Rhodobacteraceae. Von Trappen 
et al. (2) originally proposed the genus to accommodate three species but it has since 
been expanded and modified to contain 15 species (3-5). Loktanella appear to be 
ubiquitously distributed in the oceans and have been isolated from Antarctic to sub-
tropical environments (1,2). The strain YPC211 produces a beige/yellow pigment and 
was isolated from the egg mass of an American Lobster Homarus americanus 
collected in Narragansett Bay near Jamestown Island, Rhode Island, USA. 
 No natural products have been isolated from this genus despite widespread 
genomic sequencing. We present the first documented natural product, biosynthesis 
and bioactivity for this strain. This strain was isolated from eggs, which often retain a 
specific communities of microorganisms that contribute to the protection against 
infection. Bacteria isolated from crustacean egg masses have previously been found to 
produce secondary metabolites that aid in the protection of the eggs. Initial 
investigation of extracts from YPC211 monocultures did not yield antimicrobial 
bioactivity. Therefore a co-culturing approach was undertaken since such approaches 
have previously been successful in activating silent biosynthetic gene clusters (6). 
 
1.1 Sampling and Isolation 
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Bacterial isolations were carried out from field collection swabs of live wild 
Lobsters in Narragansett Bay (12/16/15; Fort Weatherall, Jamestown, RI, USA) as 
outlined in appendix I. This particular isolated was from an egg mass which harbored 
a diverse range of antimicrobial producing bacteria and was isolated on YP30 agar 
supplemented with chitin (30 g/L) from a 100-fold dilution. 
 
1.2 Genomic Sequencing and Biosynthetic Gene Cluster Analysis 
  
 Loktanella sp. constitutes a biosynthetically diverse and relatively unstudied 
genus, therefore whole genome sequencing was carried out for strain YPC211 and 
published as manuscript 5.  A comparison of secondary metabolite gene clusters was 
made across the 12 genomes sequenced for Loktanella and available through NCBI 
(Table 1). Further computational approaches were used to determine potential BGCs 
responsible for the antibiotic effects observed lead to the investigation of a non-
ribosomal peptide synthase (NRPS) BGC (Figure 1). Sequence antibiotic biosynthetic 
cassettes were analyzed for identity through Geneious and NCBI-delta-blastp. 
 
1.3 CAS Iron Binding Affinity Assay 
 
 To qualitatively detect siderophore production in Loktanella maritima 
YPC211the strain supernatant was tested in liquid chrome azurol S (CAS) indicator. A 
CAS solution was prepared according to the reported method (Schwyn & Neilands; 
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1987). Overnight liquid cultures grown in iron-limited media were centrifuged 10,000 
rpm for 1 minute and supernatant was combined in a 1:1 ratio with CAS reagent. 
 
1.4 Chemical Characterization of Loktanella maritima strain YPC211 
 
Initial screenings outlined in appendix I indicated that the strain YPC211 was 
able to produce a ZOI when spot plated against putative pathogens. However, no 
monoculture secondary metabolite extract was able to induce a ZOI. To tackle this 
problem Thalassobius sp. I31.1 and bacterial isolate Loktanella maritima YPC211 
were grown from stock on YP30 agar plates at 25 °C for 48 h. Single colonies were 
picked and inoculated into 5 mL of sterile artificial seawater supplemented with yeast 
(1 g/L) and peptone (5 g/L) and incubated at 25 ºC with shaking at 150 rpm for 48 h. 
Two 2 L Erlenmeyer flasks containing YP30 media were inoculated with 1 mL of 
dense culture and allowed to grow under the same conditions for 48 h. Two 50 mL 
samples of equally dense cultures of Thalassobius sp. and Loktanella sp. were taken 
according to OD600 readings. The Thalassobius sp. was autoclaved and the samples 
were centrifuged at 5,000 rpm for 30 minutes. The cells were washed 3 times with 
ASW and combined in 1 L of fresh YP30 incubated for 5 days at 25 oC and 150 rpm 
(New Brunswick) in the presence of Amberlite XAD-16 resin (Sigma Aldrich). 
Resin was filtered through a double layer of cheesecloth, washed with 700 mL of DI 
water and dried.  
Resin was eluted with a first wash of 250 mL DCM and 250 mL of methanol 
followed by 250 mL of methanol. The crude extract was concentrated via rotary 
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evaporation. The resulting extract was partitioned between ethyl acetate (EtOAc) and 
water 3 times in a 2 L glass separatory funnel. The organic fraction was concentrated 
by rotary evaporation before further purification. Preliminary screening for bioactivity 
utilized bioassay guided 96 well plate fractionation from the crude extract and tested 
all peaks against V. anguillarum NB10Sm. Results from this indicated a single active 
peak (Figure 2). The active peak showed a strong 254 nm absorbance used to target it 
in further purifications. 
Large-scale chemical separation methods are summarized in figure 3. Once the 
active peak was established a high throughput targeted fractionation strategy could be 
employed using solid-phase extraction (SPE) and carried out on a CombiFlash Rf200 
system equipped with a 13 g C18 RediSepRf High Performance Gold column 
(Teledyne ISCO). Solvent gradient of 5-100% B (methanol with 0.1% water formic 
acid) was run over 28 minutes. The mobile phase was initially held at 95 % solvent A 
(water with 0.1% water formic acid) for 4 minutes before starting the gradient and was 
held at 100% solvent B for 4 minutes after the gradient was completed. Individual 
peaks were collected according to absorbances at 254 nm and then concentrated in 
vacuo.  This yielded 6 fractions which were further separated using high performance 
liquid chromatography (HPLC). HPLC experiments were performed on a Shimadzu 
prominence-I LC-2030C equipped with a PDA detector model LC-2030/2040, pump 
LC-2030, and autosampler LC-2030. The HPLC method included a flow rate of 1 
mL/min, a linear gradient of MeOH against H2O (0.1% formic acid) and an XBridge 
BEH 5 µm C18, 130 Å, column (4.6 mm X 250 mm) as the stationary phase. 
Chromatography method: 5% MeOH for 4 minutes, linear gradient to 100% MeOH 
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over 16 minutes, maintain 100% MeOH for 4 minutes, return to 5% MeOH for 4 
minutes. 
Chemical characterization of pure compounds was undertaken using mass 
spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy and optical 
rotations. An accurate mass spectrum for agrobactin was acquired by electrospray 
ionization mass spectrometry (ESIMS) using an AB Sciex TripleTOF 4600 
spectrometer in the positive ion mode (Figure 4). Validation of agrobactin structure 
was carried out by MS/MS fragmentation (Figure 5). 1H NMR experiments were 
conducted using a 500 MHz Varian NMR (Varian Inc., Palo Alto, CA, USA) with 
DMSO-d6 as the solvent at 25 oC (Figure 6). 
 
1.5 Bioassay guided fractionation, disc diffusion and minimum inhibitory 
concentration (MIC) antibiotic determination and quantification 
  
 Once purity of the active peak was established (Figure 7) disc diffusion assays 
were carried out as a bioactivity guided fractionation strategy. V. parahaemolyticus 
was grown from stock on YP30 agar at 25 °C for 24 h, then in 5 mL of YP30 at 25 °C 
shaking at 150 rpm for 24 h. The dense culture was spread onto fresh YP30 agar. 
Organic fractions were dissolved in MeOH at a concentration of 20 mg/mL and loaded 
onto discs at final concentrations of 100 µg and 200 µg, dried, and placed onto the 
plate, and the plate was grown for 24 h at 25 °C. Plates were observed for zones of 
inhibition (Figure 8).  
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Minimum inhibitory concentration (MIC) was determined using a broth 
dilution assay in a 96-well plate, methanol was the vector for compound testing, and 
ciprofloxacin at 0.4 µg/mL was a positive control. Plate was incubated shaking at 
room temperature. Absorbance readings were taken hourly at 600 nm for 24 h 
(Spectromax). The MIC of agrobactin (HR1-149-2) was determined to be 50 µg/mL 
against V. parahaemolyticus (Figure 9). 
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Table 1: Data obtained from NCBI for all known genomes of Loktanella and run 
through antiSMASH cluster analysis. *indicates no biosynthetic gene clusters 
identified by antiSMASH. 
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Figure 1: NRPS biosynthetic gene cluster analysis and alignment to known gene 
clusters. Binding pocket sequence analysis was used to predict the substrate 
specificity.
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Figure 2: Initial chemical screening, 96 well plate fractionation from crude extract to 
identify the peak responsible for the observed antibiotic activity. 
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Figure 3: Large scale chemical isolation of agrobactin from a co-culture of Loktanella 
maritima YPC211 and Thalassobius sp. strain I31.1.
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Figure 4: High resolution tandem mass spectrometry intensity from direct injection 
ESI in positive ion mode (declustering potential 150 collision energy 30) for 
agrobactin m/z 637.2566 [M+H]+, 659.2373 [M+Na]+, and 681.2185 [M+Fe]+. 
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Figure 5: Direct injection TOF MS/MS fragmentation positive ion mode of agrobactin 
m/z 637.2 [H+H]+ to produce identifiable building blocks and structure confirmation. 
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Figure 6: Proton NMR spectrum of agrobactin Varian NMR 500 MHz with DMSO-
d6 as the solvent at 25 oC. 
  
  
 
 
 
218
 
Figure 7: Analytical HPLC chromatogram of agrobactin as purified product. 
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Figure 8. Disc diffusion assay indicating that only crude extracts from co-cultures of 
Thalassobius I31.1 and L. maritima YPC211 are  able to elicit an antibiotic effect 
against V. anguillarum NB10Sm. Positive control is ciprofloxacin, negative controls 
are crude media extract and methanol blank. Testing monoculture extracts of 
Thalassobius I31.1 and L. maritima YPC211. 
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Figure 9. MIC assay for agrobactin (HR1-149-2) against MRSA plotted as averages 
and standard deviation * P<0.05 ** P<0.01 from agrobactin (methanol) and 
ciprofloxacin (DMSO). Cell density measured by optical density (600 nm 
absorbance). 
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